




Table 1. Diastereoselective Conjugate Addition of Organometallics to Scalemic  $\alpha,\beta$ -Unsaturated Esters

| entry | R <sub>1</sub>  | R*OH <sup>a</sup> | RM   | T, °C | % yield | % ee | R/S | ref |
|-------|---|-------------------|--|-------|---------|------|-----|-----|
| 1     | Me  | 1                 | PhMgBr/cat. CuCl   | -15   | 61      | 58   | R   | 8   |
| 2     |   | 4                 |  | -8    | 64      | 10   | R   | 9   |
| 3     |   | 2                 |  | -15   | 50      | 68   | R   | 8   |
| 4     |   | 3                 |  |       | 58      | 74   | R   |     |
| 5     | Ph  | 1                 | <i>n</i> -BuMgCl/CuCl  |       | 56      | 17   | (-) |     |
| 6     |   | 4                 |  |       | 61      | 27   | (-) |     |
| 7     |   | 2                 |  |       | 40      | 22   | (-) |     |
| 8     |   | 3                 |  |       | 58      | 17   | (-) |     |
| 9     | Me  | 5                 | PhCu·BF <sub>3</sub>   | -70   | 76      | >99  | R   | 12  |
| 10    |   |                   | <i>n</i> -BuCu·BF <sub>3</sub>   |       | 75      | >99  | R   |     |
| 11    | Me ( <i>Z</i> isomer)   |                   | PhCu·BF <sub>3</sub>   |       | 36      | 24   | S   |     |
| 12    | Me ( <i>Z</i> isomer)   |                   | <i>n</i> -BuCu·BF <sub>3</sub>   |       | 76      | 70   | R   |     |
| 13    | <i>n</i> -Bu  |                   | MeCu·BF <sub>3</sub>   |       | 28      | 78   | R   |     |
| 14    |   |                   | MeCuP( <i>n</i> -Bu) <sub>3</sub> ·BF <sub>3</sub>   |       | 96      | 87   | R   | 13  |
| 15    |   | 7                 |  |       | 82      | 94   | R   |     |
| 16    |   |                   | LiCu(CN)Me·BF <sub>3</sub>   |       | 80      | 82   | R   |     |
| 17    | Et  |                   | MeCuP( <i>n</i> -Bu) <sub>3</sub> ·BF <sub>3</sub>   |       | 85      | 92   | R   |     |
| 18    |   |                   | LiCu(CN)Me·BF <sub>3</sub>   |       | 76      | 80   | R   |     |
| 19    | <i>n</i> -octyl   | 6                 | MeCuP( <i>n</i> -Bu) <sub>3</sub> ·BF <sub>3</sub>   |       | 90      | 98   | S   |     |
| 20    | Me  | 7                 | (CH <sub>3</sub> ) <sub>2</sub> C=CH(CH <sub>2</sub> ) <sub>2</sub> CuP( <i>n</i> -Bu) <sub>3</sub> ·BF <sub>3</sub> |       | 81      | 98   | S   |     |
| 21    | (CH <sub>3</sub> ) <sub>2</sub> C=CH(CH <sub>2</sub> ) <sub>2</sub> | 6                 | MeCuP( <i>n</i> -Bu) <sub>3</sub> ·BF <sub>3</sub>   |       | 90      | 92   | S   |     |
| 22    | Me  | 7                 | (CH <sub>2</sub> =CH)CuP( <i>n</i> -Bu) <sub>3</sub> ·BF <sub>3</sub>  |       | 85      | 94   | R   | 15  |
| 23    |   |                   | (CH <sub>2</sub> =CCH <sub>3</sub> )CuP( <i>n</i> -Bu) <sub>3</sub> ·BF <sub>3</sub>                                 |       | 86      | 99   | R   |     |
| 24    | CH <sub>2</sub> =CH(CH <sub>2</sub> ) <sub>2</sub>                  |                   |  |       | 89      | 98   | R   |     |
| 25    | Me  | 8                 | <i>n</i> -PrCuP( <i>n</i> -Bu) <sub>3</sub> ·BF <sub>3</sub>   |       | 98      | 95   | S   | 18  |
| 26    |   |                   | <i>n</i> -BuCuP( <i>n</i> -Bu) <sub>3</sub> ·BF <sub>3</sub>   |       | 89      | 97   | S   |     |
| 27    |   |                   | (CH <sub>2</sub> =CH)CuP( <i>n</i> -Bu) <sub>3</sub> ·BF <sub>3</sub>  |       | 80      | 98   | R   |     |
| 28    |   |                   | (CH <sub>3</sub> CH=CH)CuP( <i>n</i> -Bu) <sub>3</sub> ·BF <sub>3</sub>  |       | 84      | 94   | R   |     |
| 29    | <i>n</i> -Pr  |                   | MeCuP( <i>n</i> -Bu) <sub>3</sub> ·BF <sub>3</sub>   |       | 89      | 94   | R   |     |
| 30    | <i>n</i> -Bu  |                   |  |       | 93      | 97   | R   |     |
| 31    | Me  | 9                 | ( <i>n</i> -Bu) <sub>2</sub> CuLi  | -25   | 90      | 0    | (-) | 20  |
| 32    |   | 10                |  |       | 81      | 50   | S   |     |
| 33    |   | 11                |  |       | 77      | 60   | S   |     |
| 34    |   | 12                |  |       | 73      | 33   | S   |     |
| 35    |   |                   |  | -78   | 71      | 45   | S   |     |
| 36    |   | 13                |  | -25   | 75      | 87   | S   |     |
| 37    |   |                   |  | -78   | 74      | 95   | S   |     |
| 38    |   |                   | <i>n</i> -BuCu/TMSI  | -60   | 93      | 98   | S   | 21  |
| 39    |   | 14                | CCl <sub>3</sub> Li  | -110  | 85      | 24   | R   | 22  |
| 40    |   |                   | CCl <sub>3</sub> MgCl  |       | 99      | 97   | S   |     |
| 41    | Me  |                   | EtCu·BF <sub>3</sub>   | -80   | 90      | 99   | R   | 23  |
| 42    |   | 15                |  |       | 84      | 99   | S   |     |
| 43    |   | 14                | <i>i</i> -PrCu·BF <sub>3</sub>   |       | 90      | 99   | R   |     |
| 44    |   | 15                |  |       | 97      | 96   | S   |     |
| 45    | Et  | 14                | MeCu·BF <sub>3</sub>   |       | 86      | 98   | S   |     |
| 46    |   | 15                |  |       | 88      | 99   | R   |     |
| 47    |   | 14                | <i>i</i> -PrCu·BF <sub>3</sub>   |       | 96      | 99   | S   |     |
| 48    |   | 15                |  |       | 94      | 99   | R   |     |
| 49    | <i>i</i> -Pr  | 14                | MeCu·BF <sub>3</sub>   |       | 92      | 99   | R   |     |
| 50    |   | 15                |  |       | 93      | 99   | S   |     |
| 51    |   | 14                | EtCu·BF <sub>3</sub>   |       | 76      | 99   | R   |     |
| 52    |   |                   | Cu·BF <sub>3</sub>   |       | 81      | 97   | R   |     |
| 53    |   | 15                |  |       | 98      | 99   | S   |     |
| 54    | Me  | 14                | (CH <sub>2</sub> =CH)Cu·BF <sub>3</sub>  |       | 94      | 99   | S   |     |
| 55    |   | 15                |  |       | 81      | 99   | R   |     |
| 56    |   | 14                | PhCu·BF <sub>3</sub>   |       | 97      | 99   | S   |     |
| 57    |   | 15                |  |       | 94      | 99   | R   |     |
| 58    |   |                   | <i>p</i> -(CH <sub>3</sub> ) <sub>6</sub> H <sub>4</sub> Li  |       | 85      | 99   | R   |     |
| 59    |   | 16                | Ph <sub>2</sub> CuLi   | -50   | 66      | 88   | R   | 24a |
| 60    | Ph  |                   | Me <sub>2</sub> CuLi   | -30   | 71      | 84   | S   |     |
| 61    | Et  |                   | Ph <sub>2</sub> CuLi   |       | 63      | 72   | R   |     |
| 62    | Me  |                   | ( <i>n</i> -Bu) <sub>2</sub> CuLi  |       | 91      | 72   | S   |     |
| 63    | Ph  |                   |  |       | 79      | 82   | S   |     |
| 64    |   |                   | <i>n</i> -BuCu·BF <sub>3</sub>   | -78   | 33      | 25   | S   |     |
| 65    | Ph  |                   | <i>n</i> -BuMgBr   |       | 15      | 38   | S   |     |
| 66    |   |                   | <i>n</i> -BuLi   |       | 20      | 68   | R   |     |
| 67    | Et  |                   | PhLi   |       | 31      | 82   | S   |     |
| 68    | Me  | 17                | Ph <sub>2</sub> CuLi   | -30   | 60      | 28   | R   | 24b |
| 69    |   | 18                |  |       | 88      | 84   | S   |     |
| 70    |   | 19                |  | 0     | 87      | 36   | S   |     |

Table 1. (Continued)

| entry | R <sub>1</sub>                     | R*OH <sup>a</sup> | RM   | T, °C | % yield | % ee | R/S   | ref |
|-------|------------------------------------|-------------------|--|-------|---------|------|-------|-----|
| 71    |                                    | 20                |  | -30   | 55      | 34   | R     |     |
| 72    |                                    | 21                |  | 0     | 23      | 20   | R     |     |
| 73    |                                    | 16                | PhMgBr-CuI   | -78   | 46      | 56   | R     |     |
| 74    |                                    | 18                |  |       | 52      | 86   | S     |     |
| 75    |                                    |                   | (H <sub>2</sub> C=CH)MgBr-CuI                            |       | 42      | 88   | S     |     |
| 76    |                                    |                   | EtMgBr-CuI   |       | 51      | 78   | R     |     |
| 77    |                                    | 19                | PhMgBr-CuI   |       | 45      | 2    | (-)   |     |
| 78    |                                    | 20                |  |       | 50      | 4    | (-)   |     |
| 79    |                                    | 21                |  |       | 45      | 6    | (-)   |     |
| 80    | (CH <sub>2</sub> ) <sub>3</sub> Cl | 16                | Ph <sub>2</sub> CuLi                                     | 0     | 50      | 76   | 1R,2R | 24a |
| 81    |                                    |                   | n-Bu <sub>3</sub> CuLi                                   |       | 51      | 80   | 1R,2S |     |
| 82    |                                    |                   | Me <sub>2</sub> CuLi                                     |       | 57      | 76   | 1R,2S |     |
| 83    | (CH <sub>2</sub> ) <sub>4</sub> I  |                   | Ph <sub>2</sub> CuLi                                     |       | 61      | 78   | 1R,2R |     |
| 84    | Ph                                 | 5                 | (PhMe <sub>2</sub> Si) <sub>2</sub> CuLi <sub>2</sub> CN | -78   | 82      | 20   | R     | 25  |
| 85    |                                    | 7                 |  |       | 74      | 8    | R     |     |
| 86    |                                    | 8                 |  |       | 77      | 88   | R     |     |
| 87    | Me                                 |                   |  |       | 74      | 10   | S     |     |
| 88    | i-Pr                               |                   |  |       | 74      | 56   | R     |     |
| 89    | PhMe <sub>2</sub> Si               |                   | PhMgBr/CuCN  |       | 71      | 74   | R     |     |
| 90    |                                    |                   | MeMgI/Cu(OAc) <sub>2</sub>                               | -15   | 76      | 54   | S     |     |

<sup>a</sup> R\*OH =

metallic reagents, the most common of which are organolithiums,<sup>2</sup> Grignards,<sup>2</sup> and cuprates.<sup>3</sup> The primary advantage of these reactions is that they allow the direct introduction of nonstabilized organic moieties into an organic structure with high chemo- and regioselectivity starting from substrates which are generally readily available.


An important characteristic of these reactions is that they transform an sp<sup>2</sup> carbon into an sp<sup>3</sup> carbon through addition of the R moiety to the β-position. Where R<sub>1</sub> ≠ R<sub>2</sub>, this transformation can, in principle, occur enantioselectively.<sup>4</sup> Enantioselective conjugate addition (referred to hereafter as ECA) can be achieved in two ways: (1) by reaction of an achiral reagent with a scalemic substrate,<sup>5</sup> or (2) by reaction of a chiral reagent with a prochiral substrate. In cases where the starting substrate is chiral, the reaction can occur diastereoselectively. Diastereoselective conjugate addition (referred to hereafter as DCA) can lead to the synthesis of enantiomers if the original source of chirality is removed. Thus in cases where an achiral reagent reacts with a substrate in which Z is chiral, an unequal mixture of diastereomers will usually be produced by relative

asymmetric induction. Modification of Z to eliminate its stereogenic elements will produce an enantiomeric rather than diastereomeric mixture of isomers. Alternatively, one may react a prochiral substrate with a chiral reagent which induces ECA of an achiral moiety to the substrate. In this paper, we review synthetic methods which have been developed and reported for enantioselective carbon-carbon bond formation via conjugate addition of organometallic reagents to unsaturated organic substrates using either of the two strategies mentioned above. We will not review diastereo- or enantioselective conjugate addition involving stabilized carbon nucleophiles or non-carbon nucleophiles.<sup>4</sup> We will also not review reactions involving conjugate addition to racemic substrates or reactions in which the objective is not to obtain enantiomerically pure products. The review is divided into three sections. The first section reviews synthetic methods developed for DCA to scalemic substances giving diastereomerically enriched products which are subsequently transformed to enantiomers. The second and third sections review chiral reagents developed to react enantioselectively with prochiral substrates.


## II. Diastereoselective Conjugate Addition to Scalemic Substrates

### A. $\alpha,\beta$ -Unsaturated Esters

One of the first methods developed for asymmetric conjugate addition involves the reaction of organocupper reagents with enantiomerically enriched  $\alpha,\beta$ -unsaturated esters (Table 1). These esters, derived from scalemic alcohols and  $\alpha,\beta$ -unsaturated carboxylic acids, react to give diastereomeric products which upon hydrolysis yield enantiomers. In principle, this provides a simple and economical method of obtaining enantiomerically enriched products, especially if the alcohol used is readily available and recovered without racemization. It has been known for some time that copper(I) salts catalyze the conjugate addition of Grignard reagents to  $\alpha,\beta$ -unsaturated ketones<sup>6</sup> and esters.<sup>7</sup> In 1966, Kawana and Emoto reported the copper(I)-catalyzed addition of phenylmagnesium bromide to the 1,2:5,6-di-*O*-isopropylidene- $\alpha$ -D-glucose ester of crotonic acid, **22** (eq 2).<sup>8,9</sup> This reaction, followed by hydrolysis, gives (*R*)-(-)-3-phenylbutanoic acid (**23**) in 70% ee. Difficulties in reproducing these results have been reported.<sup>10</sup> Reactions with similar substrates give product with ee's ranging from 10 to 74% (entries 1–8).




Yamamoto and Maruyama described the use of  $\text{RCuBF}_3\cdot\text{Et}_2\text{O}$  for conjugate addition of R to  $\alpha,\beta$ -unsaturated carbonyl compounds.<sup>11</sup> Oppolzer and Löhner used this method for DCA to (-)-8-phenylmenthyl derived enoates (entries 9–13).<sup>12</sup> For example, reaction of  $\text{PhCu}\cdot\text{BF}_3$  with (-)-8-phenylmenthyl crotonate (**24**) gives, after hydrolysis, (*R*)-**23** in 76% yield and >99% ee (eq 3). Mediocre results were obtained with *Z* isomers




or with tri- and tetrasubstituted enoates. The high diastereoselectivity is believed to occur as a result of the ester assuming a conformation in which the carbonyl group, the ether oxygen, and the alkoxy C–H bond are coplanar and the carbonyl group and alkene are antiplanar. The phenyl group blocks one face of the alkene directing conjugate addition to the opposite face.  $\text{MeCu}\cdot\text{BF}_3$  reacts with significantly poorer diastereoselectivity. Subsequently, Oppolzer et al. demonstrated that other chiral enoates, in which the substrate is made using camphor-derived alcohols, **6** and **7**, could be used as well in this reaction with varying degrees of diastereoselectivity (entries 15–24).<sup>13,14</sup> Improved results were obtained by adding  $\text{P}(n\text{-Bu})_3$  to stabilize the organocupper reagent. These chiral auxiliaries and the improved method were used in the synthesis of (*S*)-citronellic acid (**27**) from **25** and **26**


### Scheme 1. Synthesis of Citronellic Acid via Diastereoselective Conjugate Addition to Scalemic Enoates



### Scheme 2. Synthesis of California Red Scale Pheromone via Diastereoselective Conjugate Addition to Scalemic Enoates




### Scheme 3. Synthesis of Vitamin E Side Chain via Diastereoselective Conjugate Addition to Scalemic Enoates



(Scheme 1)<sup>13</sup> and California red scale pheromone **29** from **28** (Scheme 2).<sup>15</sup> More than one chiral center can be established with this method. For example, the vitamin E side chain **31** was synthesized using this technology starting from (*R*)-citronellic acid. The new stereogenic center was established with 98% enantioselectivity (Scheme 3).<sup>16</sup> Similarly, mycolipenic acid (**33**) was also synthesized (Scheme 4).<sup>17</sup> Camphorsulfonamide esters, derived from alcohol **8**, have also been used (entries 25–30)<sup>18</sup> and are more efficient than the esters derived from alcohols **6** and **7**. Chiral auxiliary **8** is readily obtained in two steps from camphor-10-sulfonyl chloride making this protocol highly useful. This method was used to synthesize southern corn root-worm pheromone **35** (Scheme 5)<sup>18</sup> and norpectinatone (**36**, Scheme 6).<sup>19</sup>




**Scheme 7. Diastereoselective Conjugate Addition to Scalemic Enoates Followed by Internal Enolate Alkylation**

**Table 2. Diastereoselective Conjugate Addition to Scalemic Binaphthyl Esters**

| entry | RM <sup>a</sup>                | solvent           | % yield | % ee | R/S            |
|-------|--------------------------------|-------------------|---------|------|----------------|
| 1     | Me <sub>2</sub> CuLi           | ether-toluene     | 84      | 87   | R              |
| 2     |                                | ether             | 73      | 82   | R              |
| 3     |                                | toluene           | 77      | 74   | R              |
| 4     |                                | ether-THF-toluene | 72      | 63   | R              |
| 5     |                                | ether-DME         | 26      | 11   | R              |
| 6     |                                | THF               | 21      | 36   | S <sup>b</sup> |
| 7     |                                | ether-THF         | 62      | 63   | R              |
| 8     | Et <sub>2</sub> CuLi           | ether-toluene     | 39      | 14   | -              |
| 9     | <i>i</i> -Pr <sub>2</sub> CuLi |                   | 37      | 32   | -              |
| 10    | <i>n</i> -Bu <sub>2</sub> CuLi |                   | 71      | 58   | -              |
| 11    | MeMgBr/<br>5% CuI              | ether-THF         | 73      | 48   | S              |
| 12    |                                | ether-DME         | 31      | 49   | S              |
| 13    | EtMgBr/<br>5% CuI              | ether-THF         | 38      | 20   | - <sup>b</sup> |


<sup>a</sup> 10 equiv of reagent were used. <sup>b</sup> (*R*)-Binaphthol was used to form the ester.

By performing these reactions with substrates halogenated at the terminal carbon, such as 39, cyclized products were obtained as a result of DCA followed by internal alkylation of the intermediate enolate to give 40 (Scheme 7).

Fleming and Kindon used chiral alcohols 5, 7, and 8 to form scalemic  $\alpha,\beta$ -unsaturated esters which were then reacted with phenyldimethylsilyl cuprate reagents to give products with varying degrees of diastereomeric purity (eq 7).<sup>25</sup> They also reacted scalemic  $\alpha,\beta$ -unsaturated amides and an oxazolidine to give similar products.




Fuji et al. were able to obtain enantiomerically enriched ketones of up to 87% ee by reacting the scalemic 1,1'-binaphthol monoester of cinnamic acid 41 with a large excess of lithium cuprates or with Grignard reagents and a copper(I) catalyst (Table 2).<sup>26</sup> In this system, conjugate addition is followed by reaction with the ester group to give the  $\beta$ -substituted ketone. Interestingly, the two reagents gave products of opposite configuration. They rationalize the stereoselectivity observed by assuming a lithium chelate of the binaphthol oxygen followed by addition of the cuprate (Figure 2). They also suggest that the ortho hydrogen blocks


**Figure 2.**

the back side of the enoate system. An alternative complex is suggested to form with Grignard reagents which leads to the ketone of opposite configuration.

Another approach to DCA is to use scalemic esters in which the stereogenic elements are located in some part of the enoate other than the ester group. Alexakis et al. reported high diastereoselectivity when cinnamates bearing a scalemic oxazolidine or imidazolidine ring undergo DCA with achiral organocuprate reagents to give conjugate addition product (Table 3).<sup>27</sup> Their first attempts with analogous cyclic chiral acetals 42 yielded 43 with low de's (eq 8). Diastereoselectivity improves dramatically when one or two of the oxygens in the ring are replaced with nitrogen. Hydrolysis of the chiral rings yields the corresponding enantiomerically enriched aldehyde esters. Best results are obtained with a substrate containing an imidazolidine ring prepared from (*R,R*)-(-)-1,2-bis(methylamino)cyclohexane (entries 8-11).



Asami and Mukaiyama have used a similar approach with scalemic vinyl amins (Table 3, entries 12-16).<sup>28</sup> They suggest that complexation of the Grignard with the bridge-head nitrogen directs the reaction (Figure 3).


Scalastico and co-workers have examined the reaction of cuprates with  $\alpha,\beta$ -unsaturated aldehydes, ketones, and esters in which a norephedrine derived oxazolidine is substituted at the 4-position (Table 3, entries 17-21).<sup>29</sup> The starting materials are formed by reacting an  $\alpha,\beta$ -unsaturated aldehyde with norephedrine followed by benzyl chloroformate. A 95:5 mixture of diastereomeric oxazolidines is formed. With aldehydes and ketones, yields are improved by adding TMSCl.

**B.  $\alpha,\beta$ -Unsaturated Amides**

Mukaiyama and Iwasawa were able to obtain  $\beta,\beta$ -disubstituted carboxylic acids in good overall yield and

**Table 3. Diastereoselective Conjugate Addition of Cuprate Reagents to  $\alpha,\beta$ -Unsaturated Esters Substituted with Scalemic Acetals, Aminals, and Oxazolidines**

| entry | substrate | cuprate  | % yield                    | % ee | R/S | ref |
|-------|-----------|--|----------------------------|------|-----|-----|
| 1     |           | LiCuMe <sub>2</sub>                                      | 51                         | 55   | R   | 27  |
| 2     |           | LiCu( <i>n</i> -Bu) <sub>2</sub>                         | 68                         | 62   | R   |     |
| 3     |           | LiCuPh <sub>2</sub>                                      | 73                         | 98   | S   |     |
| 4     |           | LiCu(CH=CHCH <sub>2</sub> CH <sub>3</sub> ) <sub>2</sub> | 73                         | 82   | S   |     |
| 5     |           | LiCuMe <sub>2</sub>                                      | 43                         | 93   | S   |     |
| 6     |           | LiCu( <i>n</i> -Bu) <sub>2</sub>                         | 65                         | 70   | S   |     |
| 7     |           | LiCuMe <sub>2</sub>                                      | 57                         | 78   | R   |     |
| 8     |           |  | 85                         | 94   | S   |     |
| 9     |           | LiCu( <i>n</i> -Bu) <sub>2</sub>                         | 90                         | 95   | S   |     |
| 10    |           | LiCuPh <sub>2</sub>                                      | 84                         | 96   | R   |     |
| 11    |           | LiCu(CH=CHCH <sub>2</sub> CH <sub>3</sub> ) <sub>2</sub> | 80                         | 90   | R   |     |
| 12    |           | EtMgBr, CuI  | 73                         | 93   | R   | 28  |
| 13    |           |  | <i>n</i> -PrMgBr, CuI      | 75   | 89  | R   |
| 14    |           | <i>n</i> -BuMgBr, CuI                                    | 83                         | 93   | R   |     |
| 15    |           | <i>n</i> -C <sub>6</sub> H <sub>11</sub> MgBr, CuI       | 65                         | 92   | R   |     |
| 16    |           | PhCH <sub>2</sub> MgBr, CuI                              | 38                         | 35   | R   |     |
| 17    |           | LiCuMe <sub>2</sub>                                      | 70                         | 90   | S   | 29  |
| 18    |           |  | LiCuMe <sub>2</sub> /TMSCl | 72   | 90  | S   |
| 19    |           | LiCu( <i>n</i> -Bu) <sub>2</sub>                         | 70                         | 90   | S   |     |
| 20    |           | LiCu(CH=CH <sub>2</sub> ) <sub>2</sub>                   | 75                         | 90   | R   |     |
| 21    |           | LiCu(CH <sub>2</sub> CH=CH <sub>2</sub> ) <sub>2</sub>   | 54                         | 78   | S   |     |

**Figure 3.**

high enantioselectivity by reaction of Grignard reagents with  $\alpha,\beta$ -unsaturated amides derived from L-ephedrine (Table 4).<sup>30</sup> Initial deprotonation of the alcohol by the Grignard reagent forms an intermediate chelating magnesium complex (Figure 4). This complex is believed to help direct the approach of the subsequent Grignard to the relatively unencumbered side of the complex. Enantioselectivities as high as 99% are obtained in the final product. This method was used in the synthesis of (-)-malyngolide (45) from 44 (Scheme 8).<sup>31</sup>

Mukaiyama et al. carried out similar transformations by forming scalemic oxazepines and reacting them with Grignard reagents in the presence of nickel catalysts (Table 5).<sup>32</sup> Conjugate addition occurs to the sterically unencumbered face of the olefin (Figure 5). This method was used in the synthesis of indolmycin<sup>33</sup> (Scheme 9).

**Table 4. Diastereoselective Conjugate Addition to  $\alpha,\beta$ -Unsaturated Amides of Ephedrine**

| entry | R            | R <sub>1</sub> M                              | solvent           | % yield | % ee | config |
|-------|--------------|---|-------------------|---------|------|--------|
| 1     | Me           | <i>n</i> -BuMgBr                              | ether             | 53      | 85   | S      |
| 2     |              | PhMgBr  |                   | 55      | 95   | R      |
| 3     |              | EtMgBr  |                   | 58      | 98   | S      |
| 4     |              | <i>n</i> -C <sub>6</sub> H <sub>13</sub> MgBr |                   | 63      | 91   | S      |
| 5     | Ph           | <i>n</i> -BuMgBr                              |                   | 63      | 99   | S      |
| 6     | Et           |   |                   | 44      | 79   | S      |
| 7     | <i>n</i> -Bu | PhMgBr  |                   | 54      | 99   | R      |
| 8     |              |   |                   | 61      | 99   | R      |
| 9     | Ph           | EtMgBr  |                   | 47      | 98   | S      |
| 10    | Et           | PhMgBr  |                   | 62      | 93   | R      |
| 11    | Me           | <i>n</i> -BuMgBr                              | Me <sub>2</sub> O | 52      | 19   | S      |
| 12    |              |   | THF               | 66      | 22   | S      |
| 13    |              |   | toluene           | 57      | 48   | S      |
| 14    |              | <i>n</i> -BuLi                                | ether             | 58      | 28   | S      |
| 15    |              | <i>n</i> -BuMgCl                              |                   | 73      | 72   | S      |
| 16    |              | <i>n</i> -BuMgI                               |                   | 71      | 34   | S      |

Several studies by Soai and co-workers have also focused on DCA of organolithium and organomagnesium reagents to scalemic  $\alpha,\beta$ -unsaturated amides. One study involves DCA of Grignard reagents to scalemic  $\alpha,\beta$ -unsaturated amido alcohols derived from crotonic





Figure 4.

**Scheme 8. Enantioselective Synthesis of (-)-Malynolid**

**Table 5. Diastereomeric Conjugate Addition to Scalemic Alkylidene Oxazapinediones**

| entry | R <sub>1</sub> | R <sub>2</sub> | RM                                       | % yield | % ee | R/S      |
|-------|----------------|----------------|--|---------|------|----------|
| 1     | H              | Ph             | <i>n</i> -BuMgBr                         | 85      | 88   | <i>R</i> |
| 2     |                |                | <i>n</i> -BuMgBr/NiCl <sub>2</sub>       | 92      | 99   | <i>R</i> |
| 3     |                |                | <i>n</i> -BuMgBr/ZnCl <sub>2</sub>       | 76      | 85   | <i>R</i> |
| 4     |                |                | <i>n</i> -BuMgBr/FeCl <sub>3</sub>       | 70      | 60   | <i>R</i> |
| 5     |                |                | PhCH <sub>2</sub> MgCl                   | 75      | 9    | <i>R</i> |
| 6     |                |                | PhCH <sub>2</sub> MgCl                   | 78      | 7    | <i>R</i> |
| 7     |                |                | PhCH <sub>2</sub> MgCl/ZnCl <sub>2</sub> | 85      | 15   | <i>R</i> |
| 8     |                |                | PhCH <sub>2</sub> MgCl/FeCl <sub>3</sub> | 62      | 18   | <i>R</i> |
| 9     |                |                | PhCH <sub>2</sub> MgCl                   | 68      | 73   | <i>R</i> |
| 10    |                |                | PhCH <sub>2</sub> MgCl/NiCl <sub>2</sub> | 76      | 75   | <i>R</i> |
| 11    |                |                | PhCH <sub>2</sub> MgCl/CuI               | 64      | 71   | <i>R</i> |
| 12    |                |                | EtMgBr                                   | 94      | 99   | <i>R</i> |
| 13    | Ph             | H              | MeMgBr                                   | 85      | 92   | <i>S</i> |
| 14    |                |                | EtMgBr                                   | 94      | >99  | <i>S</i> |
| 15    |                |                | <i>n</i> -BuMgBr                         | 92      | 93   | <i>S</i> |
| 16    | Me             |                | <i>i</i> -PrMgBr                         | 55      | 82   | <i>R</i> |
| 17    |                |                | <i>n</i> -BuMgBr                         | 82      | 89   | <i>S</i> |
| 18    |                |                | PhMgBr                                   | 88      | 89   | <i>R</i> |
| 19    | Et             |                | <i>n</i> -BuMgBr                         | 78      | 62   | <i>S</i> |
| 20    |                |                | PhMgBr                                   | 84      | 99   | <i>R</i> |
| 21    | <i>i</i> -Pr   |                | MeMgBr                                   | 73      | 93   | <i>S</i> |
| 22    | <i>n</i> -Bu   |                | EtMgBr                                   | 77      | 58   | <i>R</i> |
| 23    | H              | Ph             | ( <i>n</i> -Bu) <sub>2</sub> CuLi        | 76      | >99  | <i>S</i> |
| 24    | Ph             | H              |  | 64      | 99   | <i>S</i> |
| 25    | Me             |                |  | 70      | 90   | <i>S</i> |
| 26    |                |                | Ph <sub>2</sub> CuLi                     | 79      | 66   | <i>R</i> |
| 27    | Et             |                | ( <i>n</i> -Bu) <sub>2</sub> CuLi        | 73      | 56   | <i>S</i> |
| 28    |                |                | Ph <sub>2</sub> CuLi                     | 66      | 65   | <i>R</i> |
| 29    | <i>n</i> -Bu   |                |  | 66      | 67   | <i>R</i> |

and cinnamic acids and derivatives of proline (Table 6).<sup>34,35</sup> Conjugate addition followed by hydrolysis of the 1,4-adducts yields enantiomerically enriched 3-substituted carboxylic acids with ee's  $\leq 100\%$  and recovery of the chiral auxiliary. Best results were obtained using toluene as the solvent and alkyl magnesium bromides as the organometallic reagents. The addition of a tertiary amine, especially DBU, improves





Figure 5.

**Scheme 9. Enantioselective Synthesis of Indolmycin via Diastereoselective Conjugate Addition**

**Table 6. Diastereoselective Conjugate Addition of Grignard Reagents to  $\alpha,\beta$ -Unsaturated Amides Derived from (*S*)-2-(1-Hydroxy-1-methylethyl)pyrrolidine**


| entry | substrate | R <sub>4</sub>  | tertiary amine    | solvent | % yield | % ee | ref |
|-------|-----------|-----------------|-------------------|---------|---------|------|-----|
| 1     | 50        | <i>n</i> -Bu    | DBU               | toluene | 49      | 100  | 34  |
| 2     |           |                 |                   |         | 45      | 96   |     |
| 3     |           |                 | Et <sub>3</sub> N |         | 23      | 75   |     |
| 4     |           | Et              | DBU               |         | 51      | 88   |     |
| 5     | 53        | <i>n</i> -Bu    |                   |         | 45      | 60   |     |
| 6     |           | Et              |                   |         | 21      | 53   |     |
| 7     |           | Ph              |                   |         | 47      | 67   |     |
| 8     | 50        | <i>n</i> -Bu    | -                 | THF     | 33      | 16   | 35  |
| 9     |           |                 | -                 | toluene | 52      | 37   |     |
| 10    |           |                 | DBU               |         | 81      | 88   |     |
| 11    |           |                 |                   | THF     | 39      | 89   |     |
| 12    |           |                 |                   | ether   | 62      | 69   |     |
| 13    |           |                 |                   | THF     | 27      | 50   |     |
| 14    |           |                 | TMEDA             |         | 30      | 67   |     |
| 15    |           |                 | (-)-sparteine     |         | 25      | 69   |     |
| 16    |           |                 | DBU               | toluene | 60      | 74   |     |
| 17    |           | Et              |                   |         | 66      | 82   |     |
| 18    |           | Me              |                   |         | 22      | 64   |     |
| 19    | 51        | <i>n</i> -Bu    |                   |         | 29      | 84   |     |
| 20    | 50        |                 |                   | THF     | 21      | 23   |     |
| 21    | 52        |                 |                   | toluene | 73      | 14   |     |
| 22    |           |                 | DBU               |         | 23      | 4    |     |
| 23    | 53        |                 |                   |         | 13      | 50   |     |
| 24    |           | Et              |                   |         | 27      | 69   |     |
| 25    |           | <i>n</i> -hexyl |                   |         | 23      | 68   |     |
| 26    |           |                 |                   |         | 33      | 55   |     |
| 27    |           |                 | TMEDA             |         | 22      | 66   |     |

50: R<sub>1</sub> = Ph, R<sub>2</sub> = Me, R<sub>3</sub> = H  
 51: R<sub>1</sub> = Me, R<sub>2</sub> = Me, R<sub>3</sub> = H  
 52: R<sub>1</sub> = Ph, R<sub>2</sub> = H, R<sub>3</sub> = H  
 53: R<sub>1</sub> = Ph, R<sub>2</sub> = H, R<sub>3</sub> = Me

the diastereoselectivity. Stereoselectivity virtually disappears when the hydroxyl group is converted to a methyl ether. This procedure was used to prepare (*S*)-citronellol in 63% ee.

In a similar study, Soai and Ookawa investigated the addition of organolithium reagents to *N*-cinnamoyl- and



**Table 7. Conjugate Addition of Organolithium Reagents to *N*-Cinnamoyl- and *N*-Crotonoylproline**




| entry | R <sub>1</sub> | reagent        | additive                     | equiv of additive <sup>a</sup> | % yield | % ee | R/S      |
|-------|----------------|----------------|------------------------------|--------------------------------|---------|------|----------|
| 1     | Ph             | <i>n</i> -BuLi | -                            | -                              | 24      | 21   | <i>S</i> |
| 2     |                |                | hexamethylene-tetramine      | 4.5                            | 30      | 3    | <i>R</i> |
| 3     |                |                | Me <sub>3</sub> N            |                                | 48      | 48   | <i>R</i> |
| 4     |                |                | Et <sub>3</sub> N            |                                | 36      | 49   | <i>R</i> |
| 5     |                |                | TMEDA                        |                                | 29      | 51   | <i>R</i> |
| 6     |                |                | (-)-sparteine                |                                | 41      | 57   | <i>R</i> |
| 7     |                |                | <i>N,N</i> -dimethyl-aniline |                                | 24      | 24   | <i>S</i> |
| 8     |                |                | proton sponge                |                                | 40      | 24   | <i>R</i> |
| 9     |                |                | <i>t</i> -BuOK               |                                | 35      | 6    | <i>S</i> |
| 10    |                |                | 12-crown-4                   |                                | 44      | 8    | <i>S</i> |
| 11    |                |                | DBU                          | 0.5                            | 43      | 37   | <i>R</i> |
| 12    |                |                |                              | 1.0                            | 55      | 60   | <i>R</i> |
| 13    |                |                |                              | 4.5                            | 48      | 55   | <i>R</i> |
| 14    |                |                |                              | 9.0                            | 51      | 50   | <i>R</i> |
| 15    |                |                |                              | 1.0 (B)                        | 34      | 29   | <i>S</i> |
| 16    |                |                |                              | 1.0 (C)                        | 35      | 57   | <i>R</i> |
| 17    |                |                | TMEDA                        | 4.5 (B)                        | 43      | 39   | <i>S</i> |
| 18    |                |                |                              | 4.5 (C)                        | 25      | 38   | <i>S</i> |
| 19    |                |                | sparteine                    | 4.5 (B)                        | 26      | 16   | <i>S</i> |
| 20    |                | MeLi           | DBU                          | 1.0 (A)                        | 36      | 11   | <i>S</i> |
| 21    |                |                |                              | 1.0 (B)                        | 10      | 14   | <i>R</i> |
| 22    | Me             |                |                              | 1.0 (A)                        | 60      | 37   | <i>R</i> |
| 23    |                |                |                              | 1.0 (B)                        | 47      | 10   | <i>S</i> |
| 24    |                | PhLi           |                              | 1.0 (A)                        | 29      | 14   | <i>S</i> |
| 25    |                |                |                              | 1.0 (B)                        | 33      | 8    | <i>R</i> |

<sup>a</sup> Order of addition: (A) amide, additive, *n*-BuLi; (B) amide, *n*-BuLi, additive; and (C) amide, mixture of *n*-BuLi and additive.


*N*-crotonoylproline (Table 7).<sup>36</sup> They discovered again that both synthetic yields and diastereoselectivities increase with the addition of tertiary amines. They also reported that the order of addition of reagents determines the configuration of the predominant isomer. Addition of the amine to the reaction mixture containing the substrate followed by the organolithium reagent produces the *R* isomer in diastereoselectivities of ≤60% (entries 20, 22, and 24). Addition of the lithium reagent before the amine or addition of a mixture of the amine and the lithium reagent yields the *S* isomer with lower diastereoselectivities (entries 21, 23, and 25). Acidic hydrolysis subsequently yields 3-substituted carboxylic acids with enantiomeric excesses of up to 60%. Tomioka, Suenaga, and Koga reported a study in which a scalemic  $\gamma$ -butyrolactam is used as a chiral auxiliary to form 3-substituted carboxylic acids (Table 8).<sup>37</sup> Conjugate addition occurs to the  $\alpha$  face to give the scalemic product.

### C. *N*-Enoyl Sultams

Similar to their work with chiral enoates, Oppolzer et al. have reported the DCA of organocopper and Grignard reagents to *N*-enoyl sultams readily derived from (+)- and (-)-camphor-10-sulfonyl chloride (Table 9).<sup>38,39</sup> The primary advantages of working with sultams are that the starting material and product are conveniently purified by recrystallization, the stereochemistry of the product is readily discerned and the sultam group is easily removed under mild conditions. The first application of this methodology was the DCA of phosphine-stabilized alkenyl- and alkylcopper reagents to

**Table 8. Diastereoselective Conjugate Addition to Scalemic Imides**



| entry | R <sub>1</sub> | RMgCl         | % yield | % ee |
|-------|----------------|---------------|---------|------|
| 1     | Me             | <i>p</i> -Tol | 85      | 89   |
| 2     |                | Ph            | 89      | 94   |
| 3     |                | cyclohexyl    | 88      | 77   |
| 4     |                | <i>n</i> -Bu  | 91      | 92   |
| 5     |                | Et            | 75      | 80   |
| 6     |                | vinyl         | 82      | 88   |
| 7     | <i>n</i> -Bu   | Ph            | 77      | 96   |
| 8     |                | cyclohexyl    | 76      | 97   |
| 9     |                | Et            | 88      | 81   |
| 10    |                | vinyl         | 90      | 85   |


**Figure 6.**

*N*-[ $\alpha$ -(silyl)enoyl] sultams with up to 96% de (entries 1–10). The reaction also works well with silylcopper reagents (entry 11). Subsequent removal of the sultam group yields the enantiomerically enriched carboxylic acid. The steric course of the reaction is believed to occur by formation of the complex shown in Figure 6 followed by addition of the organic group to the face of the olefin shown. Addition of lithium cuprate reagents to these substrates also occurs readily with good diastereoselectivity.

Oppolzer et al. have also described the DCA of methyl, vinyl, and aryl organometallic reagents to (*E*)-*N*-enoyl sultams, followed by asymmetric protonation or alkylation of the enolate which gives a product with two new stereogenic centers (Table 10).<sup>40,41</sup> This method has been used in the synthesis of  $\beta$ -necrodol (49) from 47 (Scheme 10).<sup>42</sup>


### D. 2-Cycloalkenones

One of the first effective protocols for the synthesis of enantiomerically enriched 3-substituted cyclic ketones was that developed by Posner and co-workers.<sup>43</sup> According to this method, 2-*p*-(tolylsulfinyl)-2-cycloalkenones, readily synthesized in two steps from 2-bromocycloalkenones, are treated with one of several organometallic reagents which react to give conjugate addition (Table 11). Cuprates react sluggishly. Reaction of (*S*)-2-(*p*-tolylsulfinyl)-2-cyclopentenone with R<sub>2</sub>Mg, in the absence of other salts, gives the *S* product in high de. A reversal in selectivity was observed when ZnBr<sub>2</sub> was added to the sulfinyl ketone followed by addition of Grignard reagents. Reaction with (*i*-PrO)<sub>3</sub>TiCl/RLi gave high de's. Improvements in de's

Table 9. Diastereoselective Conjugate Addition to *N*-Enoyl Sultams


| entry | R <sub>1</sub>      | RM   | Lewis acid                        | % de | % de <sup>a</sup> | % yield <sup>a</sup> | ref |
|-------|---------------------|--|-----------------------------------|------|-------------------|----------------------|-----|
| 1     | SiPhMe <sub>2</sub> | CH <sub>2</sub> =CHCu·P( <i>n</i> -Bu) <sub>3</sub>                | BF <sub>3</sub> ·OEt <sub>2</sub> | 44   | 94                | 60                   | 38  |
| 2     |                     |  | EtAlCl <sub>2</sub>               | 90   | 96                | 57                   |     |
| 3     |                     | ( <i>Z</i> )-CH <sub>3</sub> CH=CHCu·P( <i>n</i> -Bu) <sub>3</sub> |                                   | 96   | 98                | 65                   |     |
| 4     |                     | ( <i>E</i> )-CH <sub>3</sub> CH=CHCu·P( <i>n</i> -Bu) <sub>3</sub> |                                   | 96   | 96                | 67                   |     |
| 5     |                     | MeCu·P( <i>n</i> -Bu) <sub>3</sub>                                 |                                   | 86   | 93                | 61                   |     |
| 6     |                     | EtCu·P( <i>n</i> -Bu) <sub>3</sub>                                 |                                   | 86   | 92                | 62                   |     |
| 7     |                     | <i>n</i> -PrCu·P( <i>n</i> -Bu) <sub>3</sub>                       |                                   | 88   | 96                | 57                   |     |
| 8     |                     | <i>i</i> -PrCu·P( <i>n</i> -Bu) <sub>3</sub>                       |                                   | 86   | 94                | 64                   |     |
| 9     |                     | <i>n</i> -BuCu·P( <i>n</i> -Bu) <sub>3</sub>                       |                                   | 92   | 97                | 61                   |     |
| 10    |                     | PhCu·P( <i>n</i> -Bu) <sub>3</sub>                                 |                                   | 94   | 100               | 86                   |     |
| 11    | Ph                  | SiPhMe <sub>2</sub> Cu·P( <i>n</i> -Bu) <sub>3</sub>               |                                   | 80   | 97                | 43                   |     |
| 12    | Me                  | EtMgCl   | —                                 | 89   | —                 | 80                   | 39  |
| 13    |                     | <i>n</i> -PrMgCl   | —                                 | 85   | —                 | 90                   |     |
| 14    |                     | <i>i</i> -PrMgCl   | —                                 | 72   | —                 | 92                   |     |
| 15    |                     | <i>n</i> -BuMgCl   | —                                 | 86   | —                 | 78                   |     |
| 16    |                     | <i>n</i> -C <sub>6</sub> H <sub>13</sub> MgCl                      | —                                 | 84   | —                 | 73                   |     |
| 17    |                     | <i>n</i> -C <sub>8</sub> H <sub>17</sub> MgCl                      | —                                 | 82   | —                 | 81                   |     |
| 18    | Et                  | <i>n</i> -BuMgCl   | —                                 | 89   | —                 | 89                   |     |

<sup>a</sup> After recrystallization of the product sultam.

Table 10. Diastereoselective Conjugate Addition to *N*-Enoyl Sultams and Subsequent Treatment of the Enolate with an Electrophile



| entry | R <sub>3</sub> M                        | R <sub>1</sub> | R <sub>2</sub>                                    | E-X  | A/B/C/D <sup>a</sup> | % yield <sup>b</sup> | % purity <sup>c</sup> | config                 | ref |
|-------|---|----------------|---|--|----------------------|----------------------|-----------------------|------------------------|-----|
| 1     | <i>n</i> -BuMgCl                        | H              | Me  | Me-I   | 87:0:5:9             | 48                   | 98                    | 2 <i>R</i> ,3 <i>R</i> | 39  |
| 2     |   |                | Et  |  | 88:0:3:9             | 36                   | 98                    | 2 <i>R</i> ,3 <i>R</i> |     |
| 3     | EtMgCl                                  | Me             | Me  | H-OH   | 99:0:1:0             | 81                   | 100                   | 2 <i>R</i> ,3 <i>R</i> |     |
| 4     | BuMgCl                                  |                |   | H-NH <sub>3</sub> <sup>+</sup> Cl <sup>-</sup> | 98:0:1:1             | 66                   | 100                   | 2 <i>R</i> ,3 <i>R</i> |     |
| 5     | PhMgCl                                  |                |   |  | 97:0:2:1             | 48                   | 99                    | 2 <i>R</i> ,3 <i>S</i> |     |
| 6     | <i>n</i> -BuMgCl                        |                | Et  |  | 97:0:3:0             | 78                   | 100                   | 2 <i>R</i> ,3 <i>R</i> |     |
| 7     | EtMgCl                                  |                | Bu  |  | 97:0:1:2             | 60                   | 100                   | 2 <i>R</i> ,3 <i>S</i> |     |
| 8     | <i>n</i> -BuMgCl/CuCl                   |                | Me  |  | 0:2:86:12            | 67                   | 98                    | 2 <i>S</i> ,3 <i>S</i> | 40  |
| 9     | <i>n</i> -BuMgCl/CuCN                   |                | Me  |  | 0:2:84:14            | —                    | —                     | 2 <i>S</i> ,3 <i>S</i> |     |
| 10    | EtMgCl/CuCl                             |                | Me  |  | 0:2:85:12            | 66                   | 99                    | 2 <i>S</i> ,3 <i>S</i> |     |
| 11    | <i>n</i> -BuMgCl/CuCl                   |                | Et  |  | 0:0:92:8             | 71                   | 100                   | 2 <i>S</i> ,3 <i>S</i> |     |
| 12    | EtMgCl/CuCl                             |                | Bu  |  | 0:0:97:3             | 63                   | 99                    | 2 <i>S</i> ,3 <i>R</i> |     |
| 13    | <i>n</i> -BuMgCl/CuCl                   |                | ( <i>t</i> -Bu)Me <sub>2</sub> SiOCH <sub>2</sub> |  | 0:0:97:3             | 56                   | 99                    | 2 <i>S</i> ,3 <i>S</i> |     |
| 14    | <i>n</i> -BuMgCl                        |                | ( <i>t</i> -Bu)Me <sub>2</sub> SiOCH <sub>2</sub> |  |                      | 83                   | 100                   | 2 <i>R</i> ,3 <i>R</i> |     |
| 15    | MeMgCl/CuCl                             |                | <i>n</i> -Bu                                      |  | 8:11:69:13           | —                    | —                     | 2 <i>S</i> ,3 <i>R</i> |     |
| 16    | PhMgCl/CuCl                             |                | Me  |  | 3:3:72:22            | —                    | —                     | 2 <i>S</i> ,3 <i>R</i> |     |
| 17    | Me <sub>2</sub> CuLi                    |                | Et  |  | 15:85:0:0            | —                    | —                     | 2 <i>S</i> ,3 <i>R</i> | 41  |
| 18    |   |                |   |  | 9:91:0:0             | —                    | —                     | 2 <i>S</i> ,3 <i>R</i> |     |
| 19    |   |                | <i>n</i> -Bu                                      |  | 5:89:3:4             | —                    | —                     | 2 <i>S</i> ,3 <i>S</i> |     |
| 20    |   |                | Ph  |  | 6:90:(4)             | —                    | —                     | 2 <i>S</i> ,3 <i>R</i> |     |
| 21    | Ph <sub>2</sub> CuLi                    |                | Me  |  | 11:83:0:6            | —                    | —                     | 2 <i>S</i> ,3 <i>S</i> |     |
| 22    | (CH <sub>2</sub> =CH) <sub>2</sub> CuLi |                |   |  | 12:86:0:1            | —                    | —                     | 2 <i>S</i> ,3 <i>S</i> |     |

<sup>a</sup> Ratio of the diastereomeric products before purification. <sup>b</sup> Yield of the major diastereomer after purification. <sup>c</sup> Purity of the major diastereomer after purification.

were obtained by switching from the *p*-tolylsulfinyl to *p*-anisylsulfinyl ketones.<sup>44</sup> Posner and Frye also synthesized 3-substituted cyclohexanones (65–96% enantiomeric purity) from (*S*)-2-(*p*-tolylsulfinyl)-2-cyclohexenone and various organometallic reagents.<sup>45</sup>


Normally the 2-(arylsulfinyl)-2-cycloalkenones exist in a conformation in which the sulfinyl sulfur-oxygen bond dipole and the carbonyl carbon-oxygen bond dipole are anti to one another. Reaction of diorganomagnesium compounds with these substrates in the absence of metal salts and in THF results in highly

stereoselective conjugate addition as shown (Figure 7). Addition of metal salts such as ZnBr<sub>2</sub> results in a reversal of the diastereoselectivity because of chelation with the sulfinyl and ketone oxygens which results in blocking the backside of the enone system. Furthermore, Posner and co-workers found that one generally obtains higher ee's if 2,5-dimethyltetrahydrofuran (DMTHF) is used as the solvent instead of THF. The diminished complexing ability of DMTHF to the metal ion allows more effective metal ion chelation by the bidentate β-keto sulfoxide, which in turn results in

Scheme 10. Enantioselective Synthesis of  $\beta$ -NecrodolTable 11. Diastereoselective Conjugate Addition of Organometallics to (*S*)-2-(Arylsulfinyl)-2-cycloalkenones

| entry | <i>n</i> | Ar            | RM   | solvent | % yield | % ee | <i>R/S</i> |
|-------|----------|---------------|--|---------|---------|------|------------|
| 1     | 5        | <i>p</i> -Tol | $\text{Me}_2\text{Mg}$                             | THF     | 60      | 97   | <i>S</i>   |
| 2     |          |               | $\text{Et}_2\text{Mg}$                             |         | 81      | 81   | <i>S</i>   |
| 3     |          |               | $\text{Ph}_2\text{Mg}$                             |         | 72      | 97   | <i>S</i>   |
| 4     | 6        |               | $\text{Me}_2\text{Mg}$                             |         | 50      | 79   | <i>S</i>   |
| 5     | 5        |               | $\text{MeMgCl}$                                    |         | 91      | >98  | <i>R</i>   |
| 6     |          |               | $\text{ZnBr}_2/\text{EtMgCl}$                      |         | 84      | 80   | <i>R</i>   |
| 7     |          |               | $(i\text{-Pr})_3\text{TiEt}$                       |         | 67      | >98  | <i>R</i>   |
| 8     |          |               | $\text{ZnBr}_2/t\text{-BuMgCl}$                    |         | 98      | 86   | <i>R</i>   |
| 9     |          |               | $\text{ZnBr}_2/\text{CH}_2=\text{CHMgBr}$          |         | 75      | 99   | <i>R</i>   |
| 10    |          |               | $\text{ZnBr}_2/\text{PhMgCl}$                      |         | 70      | 92   | <i>R</i>   |
| 11    |          |               | $6\text{-MeONaphthMgBr}$                           |         | 90      | >98  | <i>R</i>   |
| 12    |          |               | $\text{ZnBr}_2/\text{TolMgBr}$                     |         |         | 58   | <i>R</i>   |
| 13    |          | <i>p</i> -An  |  |         |         | 69   | <i>R</i>   |
| 14    |          | <i>p</i> -Tol |  | DMTHF   | 74      | 86   | <i>R</i>   |
| 15    |          |               | $\text{ZnBr}_2/\text{Me}_3\text{CCH}_2\text{MgCl}$ | THF     |         | 17   | <i>R</i>   |
| 16    |          |               |  | DMTHF   | 81      | 77   | <i>R</i>   |
| 17    | 6        |               | $\text{ZnBr}_2/\text{CH}_2=\text{CHMgBr}$          |         | 74      | 65   | <i>R</i>   |
| 18    |          |               | $(i\text{-PrO})_3\text{TiCl/MeLi}$                 | THF     |         | 87   | <i>R</i>   |
| 19    |          |               |  | DMTHF   | 83      | 96   | <i>R</i>   |
| 20    |          |               | $(i\text{-PrO})_3\text{TiCl/PhLi}$                 | THF     |         | 43   | <i>R</i>   |
| 21    |          |               |  | DMTHF   | 58      | 93   | <i>R</i>   |
| 22    |          |               | $(i\text{-PrO})_3\text{TiCl/EtMgBr}$               | THF     | 65      | 90   | <i>R</i>   |

## Scheme 11. Synthesis of Equinelin via Diastereoselective Conjugate Addition



higher selectivities. Posner and Frye obtained the best results using  $\text{RTi}(\text{O-}i\text{-Pr})_3$  in DMTHF or  $\text{ZnBr}_2/\text{RMgX}$  in DMTHF.

Using this methodology, Posner and co-workers were able to stereoselectively synthesize several interesting chiral substrates including equilenin (51; Scheme 11), (–)-podorhizon (53; eq 9), and (+)-A factor (54), a potent






Figure 7.


autoregulating factor essential for streptomycin production (eq 10).



Saengchantava and Wallace used this approach to synthesize enantiomerically enriched 2-substituted chroman-4-ones (eq 11).<sup>46</sup> DCA of lithium dimethyl cuprate to (*S*)-3-(*p*-tolylsulfinyl)chromone (55) gave, after chromatographic purification and removal of the sulfoxide group with aluminum amalgam, (*S*)-2-methylchroman-4-one (56) in 88% ee.



Schultz and Harrington recently reported a procedure for the synthesis of enantiomerically enriched 3-substituted cyclohexanones via DCA to salemic 2-(aminocarbonyl)-2-cyclohexenone 58.<sup>47</sup> Substrate 58 is readily obtained by Birch reduction of amide 57, followed by acid-catalyzed hydrolysis and olefin migration (eq 12). DCA with various organometallic reagents gave products 59 with diastereoselectivities ranging from 0 to 94% (Table 12). Treatment of the product with hydroxylamine results in removal of the chiral auxiliary to give the (*S*)-3-methyl cyclohexanone.




Smith, Dunlap, and Sulikowski reported the conjugate addition of Gilman's reagent to 5(*R*)-methoxy-2-cyclopentenone followed by hydrolysis and removal of the methoxy group with samarium iodide to give salemic 3-methylcyclopentanone (eq 13).<sup>48</sup> Though not developed as a method to obtain enantiomerically enriched products, such is possible, if one has access to salemic 5-methoxy-2-cyclopentenone. Other cuprates were found to react with this and other racemic cyclopentenones with moderate to high diastereoselectivities.

**Table 12. Diastereoselective Conjugate Addition to 2-(Aminocarbonyl)-2-Cyclohexenone 55**


| entry | RM                                      | RM, equiv | ZnBr <sub>2</sub> , equiv | TMSCl, equiv | % yield | % de |
|-------|---|-----------|---------------------------|--------------|---------|------|
| 1     | MeMgCl                                  | 1.5       |                           |              | 8       | 0    |
| 2     |   | 3.6       | 1.0                       | 5.0          | 80      | 67   |
| 3     | MeLi                                    | 4.0       | 1.2                       |              | 89      | 60   |
| 4     | EtMgBr                                  | 3.6       | 1.2                       |              | 54      | 94   |
| 5     | <i>n</i> -PrMgCl                        | 3.6       | 1.2                       |              | 57      | 94   |
| 6     | CH <sub>2</sub> =CHCH <sub>2</sub> MgBr | 3.6       | 1.2                       |              | 19      | 95   |
| 7     |   | 1.2       | <i>a</i>                  | 5.0          | 36      | >94  |
| 8     | CH <sub>2</sub> =CHMgBr                 | 3.6       | 1.2                       |              | 73      | >94  |
| 9     | PhMgBr                                  | 1.5       | 0                         |              | 37      | 0    |
| 10    |   | 2.0       | <i>b</i>                  | 5.0          | 99      | 67   |
| 11    |   | 3.6       | 1.2                       |              | 49      | 94   |

<sup>a</sup> 10% CuBr<sub>2</sub>. <sup>b</sup> 1.0 equiv CuBr.




Jung and Lew recently reported DCA of several cuprate reagents to scalemic enone ketals with low to moderate diastereoselectivity (Table 13).<sup>49</sup>

Vemura and co-workers have explored the conjugate addition of organocopper reagents with scalemic (*o*-methoxyphenyl 1-propenyl ketone)chromium complex.<sup>50</sup> Reaction of the (*R*)-chromium complex 60 with ((*S*)-2-methyl-3-*tert*-butoxypropyl)copper-boron trifluoride (61) gives exclusively conjugate addition with 99:1 selectivity, yielding 62 (eq 14). Reaction of the same organocopper reagent with the *S* enantiomer of the chromium complex gives the product in a ratio of 66:34. Thus, the first reaction represents a matched case and the latter a mismatched case in this reaction manifesting double diastereoselectivity. This protocol is somewhat limited because of the need to resolve the chromium complex.



### E. Vinyl Acetals, Oxazolidines, and Imidazolidines

Another approach to stereoselective conjugate addition is to react an organometallic reagent with  $\alpha,\beta$ -unsaturated aldehydes masked as acetals, oxazolidines,

**Table 13. Diastereoselective Conjugate Addition to Scalemic Ketal Enones**

| reagent                               | % de   |        |                         |                           |
|---------------------------------------|--------|--------|-------------------------|---------------------------|
|                                       | R = Me | R = Ph | R = CH <sub>2</sub> OBn | R = MeOC(Me) <sub>2</sub> |
| Me <sub>2</sub> CuLi                  | 28     | 22     | 4                       | 24                        |
| Me <sub>2</sub> Cu(CN)Li <sub>2</sub> | 26     | 2      | 20                      | 22                        |
| ( <i>n</i> -Bu) <sub>3</sub> PMeCuLi  |        |        | 20                      | 12                        |
| (Th)MeCu(CN)Li <sub>2</sub>           |        |        | 24                      |                           |
| PhCH <sub>2</sub> (CN)ZnBr            | 25     |        |                         |                           |

or imidazolidines derived from scalemic diols, amino alcohols, or diamines, respectively. Alexakis et al. reported the DCA of achiral organocopper reagents to chiral  $\alpha,\beta$ -unsaturated acetals (Table 14, entries 1–15).<sup>51</sup> They first prepared a cyclic chiral acetal from the aldehyde and a chiral diol usually having a C<sub>2</sub> axis of symmetry. Aryl-, alkenyl-, or vinylcopper with BF<sub>3</sub>·Et<sub>2</sub>O react with the vinylic acetals in an anti S<sub>N</sub>2' reaction that results in diastereoselective cleavage of the chiral acetal ring. The resulting enol ethers were easily hydrolyzed to enantiomerically enriched  $\beta$ -substituted aldehydes with recovery of the chiral diol. They obtained the highest diastereoselectivity (95%) with PhCu, BF<sub>3</sub>, and P(*n*-Bu)<sub>3</sub> as a copper(I) ligand. Conjugate addition to chiral ketals was also performed with some success (Table 15). This methodology was used to synthesize the California red scale pheromone 29 (Scheme 12).

Yamamoto and co-workers have reported DCA of Me<sub>3</sub>Al to vinyl acetals derived from  $\alpha,\beta$ -unsaturated aldehydes and ketones and *N,N,N',N'*-tetramethyltartramide with excellent diastereoselectivity (Table 14, entries 17–21).<sup>52</sup> This method was used to synthesize the side chain of vitamin E (entry 21).

Reaction of Grignard reagents and a Cu(I) catalyst with scalemic propargylic acetals gave allenes with up to 85% de (Table 16).

Berlan et al. have reported DCA of organocuprate reagents to  $\alpha,\beta$ -unsaturated oxazolidines with de's of up to 85% (Table 17).<sup>53</sup> The enantioselectivity of this reaction is highly dependent on solvent and salts present in solution. A number of mechanistic studies have been carried out which suggest the reaction occurs by 1,2-addition to the double bond rather than by S<sub>N</sub>2' addition.<sup>54</sup> Formation of more than one diastereomer of the oxazolidine from ephedrine and various  $\alpha,\beta$ -unsaturated aldehydes can often be problematic leading to difficulties in implementing this method.<sup>55</sup>

### F. Vinyl and Aryl Oxazolidines

Another highly effective means of DCA, reported by Meyers, Whitten, and Smith,<sup>56</sup> involves the addition of organolithiums to vinyl oxazolidines giving, after hydrolysis,  $\beta,\beta$ -disubstituted propionic acids (Table 18). Either enantiomer of the product can be obtained by switching R and R<sub>1</sub>. The reaction is believed to involve, first, complexation of the organolithium reagent to the nitrogen and methoxy group of the oxazolidine, followed

Table 14. Diastereoselective Conjugate Addition of Organometallic Reagents to Scalemic  $\alpha,\beta$ -Unsaturated Acetals

| entry | R <sub>1</sub>                 | Z <sup>a</sup> | reagent   | % yield | % ee | R/S | ref |
|-------|--------------------------------|----------------|---|---------|------|-----|-----|
| 1     | Me                             | 63             | PhCuSMe <sub>2</sub>  | 70      | 76   | S   | 51  |
| 2     |                                |                | PhCuP( <i>n</i> -Bu) <sub>3</sub>   | 75      | 95   | S   |     |
| 3     | ( <i>Z</i> )-Me                |                | PhCu  | 75      | 69   | R   |     |
| 4     | <i>n</i> -Pr                   | 64             | PhCuPBu <sub>3</sub>  | 71      | 91   | S   |     |
| 5     | Me                             |                | PhCuSMe <sub>2</sub>  | 70      | 77   | S   |     |
| 6     |                                |                | 65  |         | 50   | 76  |     |
| 7     |                                | ent-66         |   | 67      | 35   | R   |     |
| 8     |                                | ent-67         |   | 70      | 29   | R   |     |
| 9     |                                | 68             | (Me <sub>2</sub> C=CH) <sub>2</sub> CuLi  | 69      | 24   | ND  |     |
| 10    |                                |                | (Me <sub>2</sub> C=CH)Cu·SMe <sub>2</sub>   | 72      | 67   | ND  |     |
| 11    |                                |                |   | 70      | 85   | ND  |     |
| 12    |                                |                | [CH <sub>2</sub> =C( <i>n</i> -C <sub>5</sub> H <sub>11</sub> ) <sub>2</sub> ] <sub>2</sub> CuLi                  | 75      | 50   | ND  |     |
| 13    |                                |                | [CH <sub>2</sub> =C( <i>n</i> -C <sub>5</sub> H <sub>11</sub> ) <sub>2</sub> ] <sub>2</sub> CuLi·SMe <sub>2</sub> | 71      | 60   | ND  |     |
| 14    |                                |                | CH <sub>2</sub> =C( <i>n</i> -C <sub>5</sub> H <sub>11</sub> )CuP( <i>n</i> -Bu) <sub>3</sub>                     | 69      | 85   | ND  |     |
| 15    |                                |                | ( <i>Z</i> )-(n-C <sub>8</sub> H <sub>17</sub> )HC=CHCuSMe <sub>2</sub>   | 70      | 73   | ND  |     |
| 16    |                                |                | ( <i>Z</i> )-(n-C <sub>8</sub> H <sub>17</sub> )HC=CHCuP( <i>n</i> -Bu) <sub>3</sub>                              | 68      | 85   | ND  |     |
| 17    | <i>n</i> -Pr                   | 69             | Me <sub>3</sub> Al  | NG      | 96   | S   | 52  |
| 18    | Me                             |                | ( <i>n</i> -Pr) <sub>3</sub> Al   | 51      | 93   | R   |     |
| 19    | Ph                             |                | Me <sub>3</sub> Al  | 77      | 98   | R   |     |
| 20    | 4-methyl-3-pentenyl            | 70             |   | 61      | 96   | R   |     |
| 21    | ( <i>R</i> )-4,8-dimethylnonyl |                |   | 55      | 96   | R   |     |

<sup>a</sup> Z =

63

64

65

66

67

68

69


70


71

Table 15. Diastereoselective Conjugate Addition of Organometallic Reagents to Scalemic Ketals

| entry | substrate | reagent   | % yield | % ee | R/S | ref |
|-------|-----------|---|---------|------|-----|-----|
| 1     |           | LiCuMe <sub>2</sub> , BF <sub>3</sub> ·OEt <sub>2</sub> | 71      | 26   | S   | 51  |
| 2     |           |   |         | 48   | R   |     |
| 3     |           | AlMe <sub>3</sub> /toluene                              | 97      | 77   | R   | 52  |
| 4     |           |   | 84      | 72   | S   |     |
| 5     |           |   | 74      | 70   | S   |     |
| 6     |           |   | 84      | 54   | R   |     |

Scheme 12. Synthesis of California Red Scale Pheromone via Diastereoselective Conjugate Addition to Scalemic Vinyl Acetals



**Table 16. Copper-Catalyzed Diastereoselective Conjugate Addition of Grignard Reagents to Scalemic Propargylic Acetals**


| entry | Z <sup>a</sup> | R            | CuX                       | % de |
|-------|----------------|--------------|---------------------------|------|
| 1     | 63             | Me           | CuBr                      | 56   |
| 2     |                | <i>n</i> -Bu |                           | 70   |
| 3     |                | <i>t</i> -Bu |                           | 100  |
| 4     |                | Ph           |                           | 45   |
| 5     | 64             | Me           |                           | 28   |
| 6     | 65             |              |                           | 59   |
| 7     | 66             |              | CuBr·2P(OEt) <sub>3</sub> | 78   |
| 8     | 67             |              | CuBr                      | 30   |
| 9     | 68             |              |                           | 74   |
| 10    | 69             |              |                           | 66   |
| 11    |                |              | CuBr·2P(OEt) <sub>3</sub> | 85   |

<sup>a</sup> See Table 14 for structures.



by nucleophilic addition of the R<sub>1</sub> group to the top face of the olefin (Figure 8). The phenyl group on the oxazoline apparently has little or no effect on the stereochemical outcome of the reaction.<sup>57</sup> Stabilized carbanions add in a conjugate fashion but with little or no diastereoselectivity. Methyl lithium is also nonstereoselective in its addition to vinyl oxazolines. More recently, vinyl oxazolines, in which the oxazoline is

derived from *tert*-leucinol, have been used in this reaction and have been found to be highly effective giving products in greater than 94% ee.<sup>58</sup> In addition, mild procedures have been developed for removal of the oxazoline group facilitating recovery of the desired product.

This method has been used in the synthesis of *ar*-tumerone (76; Scheme 13)<sup>59</sup> and in carbomycins 78 and 79 (Scheme 14).<sup>60</sup>

Treatment of the intermediate azaenolate with MeI results in  $\alpha$ -alkylation with high diastereomeric excess and produces  $\alpha,\beta,\beta$ -trisubstituted propionic acids (Scheme 15).

An interesting variation of this reaction was developed for the synthesis of scalemic biaryls (Table 19). Reaction of naphthyl Grignards with scalemic (1-methoxy-2-naphthyl)oxazolines results in displacement of the methoxy group and formation of the binaphthyl (eq 15).<sup>61</sup>



**Table 17. Diastereoselective Conjugate Addition of Cuprate Reagents to Scalemic  $\alpha,\beta$ -Unsaturated Oxazolidines<sup>a</sup>**


| entry | R <sub>1</sub>                | R  | M    | solvent            | salt                               | R/S | % ee |
|-------|-------------------------------|--|------|--------------------|------------------------------------|-----|------|
| 1     | Ph                            | Me                                       | Li   | ether              | -                                  | S   | 40   |
| 2     |                               |  |      | hexane             |                                    | R   | 80   |
| 3     |                               | C <sub>2</sub> H <sub>5</sub>            |      | ether              |                                    | S   | 15   |
| 4     |                               |  |      | hexane             |                                    | R   | 10   |
| 5     |                               | C <sub>4</sub> H <sub>9</sub>            |      | ether              |                                    | S   | 20   |
| 6     |                               |  |      | ether, hexane, THF |                                    | S   | 12   |
| 7     |                               |  |      | ether              | LiBr                               | S   | 59   |
| 8     |                               | <i>t</i> -C <sub>4</sub> H <sub>9</sub>  |      | ether, hexane      | -                                  | R   | 48   |
| 9     |                               | CH=CH <sub>2</sub>                       |      | ether              |                                    | R   | 25   |
| 10    |                               |  |      | ether, hexane, THF |                                    | R   | 35   |
| 11    | <i>o</i> -ClPh                | Me                                       |      | ether              |                                    | R   | 39   |
| 12    |                               |  |      | hexane             |                                    | R   | 81   |
| 13    | <i>o</i> -MeOPh               |  |      | ether              |                                    | S   | 7    |
| 14    |                               |  |      | hexane             |                                    | R   | 70   |
| 15    | 1-naphthyl                    |  |      | ether              |                                    | S   | 35   |
| 16    |                               |  |      | hexane             |                                    | R   | 55   |
| 17    | Me                            | C <sub>2</sub> H <sub>5</sub>            |      | ether              |                                    | R   | 5    |
| 18    |                               |  |      |                    | LiBr                               | S   | 54   |
| 19    |                               | C <sub>3</sub> H <sub>7</sub>            |      |                    | -                                  | R   | 7    |
| 20    |                               |  |      |                    | LiBr                               | S   | 40   |
| 21    |                               |  | MgBr |                    | -                                  | S   | 13   |
| 22    |                               | <i>n</i> -C <sub>4</sub> H <sub>9</sub>  | Li   |                    |                                    | R   | 12   |
| 23    |                               |  |      |                    | LiBr                               | S   | 70   |
| 24    |                               |  | MgBr |                    | -                                  | S   | 25   |
| 25    |                               | <i>i</i> -C <sub>3</sub> H <sub>7</sub>  |      |                    |                                    | S   | 12   |
| 26    |                               | <i>t</i> -C <sub>4</sub> H <sub>9</sub>  | Li   |                    |                                    | S   | 16   |
| 27    |                               |  |      |                    | LiOt-C <sub>4</sub> H <sub>9</sub> | R   | 45   |
| 28    |                               | <i>c</i> -C <sub>6</sub> H <sub>11</sub> |      |                    | -                                  | S   | 6    |
| 29    |                               |  |      |                    | LiBr                               | R   | 34   |
| 30    | C <sub>3</sub> H <sub>7</sub> | Me                                       |      |                    | -                                  | S   | 14   |
| 31    |                               |  |      | hexane             |                                    | S   | 40   |
| 32    |                               |  |      | ether              | LiBr                               | R   | 51   |
| 33    |                               |  | MgBr |                    | -                                  | R   | 29   |
| 34    |                               | <i>c</i> -C <sub>6</sub> H <sub>11</sub> | Li   |                    |                                    | S   | 24   |
| 35    |                               | <i>t</i> -C <sub>4</sub> H <sub>9</sub>  |      |                    | LiBr                               | R   | 66   |

<sup>a</sup> The yields were in most cases  $\approx$  80%; the reactions were run at -40 °C.




**Table 18. Diastereoselective Conjugate Addition of Organolithiums to Scalemic Vinyl Oxazolines**

| $\text{R}_1\text{-CH=CH-OXZ} \xrightarrow[2. \text{H}_3\text{O}^+]{1. \text{RLi}, -78^\circ\text{C}} \text{R}_1\text{-CH(R)-CH}_2\text{-OXZ}$ |                                    |                  |                 |         |      |     |     |
|---|------------------------------------|------------------|-----------------|---------|------|-----|-----|
| entry   | R <sub>1</sub>                     | OXZ <sup>a</sup> | RLi             | % yield | % ee | R/S | ref |
| 1   | Me                                 | 73               | Et              | 40      | 92   | R   | 56  |
| 2   |                                    |                  | <i>n</i> -Bu    | 38      | 91   | R   |     |
| 3   |                                    |                  | <i>n</i> -hexyl | 44      | 99   | R   |     |
| 4   |                                    |                  | Ph              | 44      | 98   | S   |     |
| 5   | Et                                 |                  | <i>n</i> -Bu    | 55      | 96   | R   |     |
| 6   |                                    |                  | Ph              | 39      | 92   | S   |     |
| 7   | <i>i</i> -Pr                       |                  | <i>n</i> -Bu    | 53      | 99   | R   |     |
| 8   | <i>t</i> -Bu                       |                  |                 | 50      | 98   | R   |     |
| 9   | cyclohexyl                         |                  | Et              | 73      | 99   | R   |     |
| 10  |                                    |                  | <i>n</i> -Bu    | 79      | 99   | R   |     |
| 11  | MeOCH <sub>2</sub> CH <sub>2</sub> |                  | Et              | 54      | 95   | S   |     |
| 12  |                                    |                  | <i>n</i> -Pr    | 50      | 99   | S   |     |
| 13  |                                    |                  | <i>n</i> -Bu    | 66      | 95   | S   |     |
| 14  |                                    |                  | Ph              | 60      | 95   | S   |     |
| 15  | Ph                                 |                  | Et              | 66      | 97   | R   |     |
| 16  |                                    |                  | <i>n</i> -Bu    | 67      | 99   | R   |     |
| 17  | <i>o</i> -MeOPh                    |                  | Et              | 83      | 95   | R   |     |
| 18  |                                    |                  | <i>n</i> -Bu    | 75      | 95   | R   |     |
| 19  |                                    |                  | Ph              | 87      | 95   | R   |     |
| 20  | <i>n</i> -Bu                       | 74               |                 | 53      | 97   | S   | 58  |
| 21  | cyclohexyl                         |                  |                 | 60      | 96   | R   |     |
| 22  | Ph                                 |                  | <i>n</i> -Bu    | 53      | 96   | R   |     |
| 23  |                                    |                  | <i>t</i> -Bu    | 74      | 94   | S   |     |
| 24  | <i>o</i> -MeOPh                    |                  | <i>n</i> -Bu    | 61      | 96   | R   |     |

<sup>a</sup> OXZ as follows:**Figure 8.**

High diastereoselectivity is achieved as a result of the formation of a stereochemically preferred complex between the naphthyl Grignard and the naphthyl-oxazoline before coupling. In cases where the naphthyl Grignard has an alkyl group at the 2 position, attack in which the naphthyl ring points away from the complex is preferred. Where the 2 position has an alkoxy group, chelation of that group with the magnesium ion of the Grignard results in the formation of a complex which leads to the opposite diastereomer (Figure 9).

This same reaction can be accomplished using 2-(1-alkoxy)naphthyl oxazoline in which the alkoxy group is chiral (Table 20).<sup>62</sup>



















**Scheme 13. Synthesis of *ar*-Tumerone via Diastereoselective Conjugate Addition****Scheme 14. Synthesis of Carbomycins via Diastereoselective Conjugate Addition****Scheme 15. Diastereoselective Conjugate Addition of Organolithium Reagents to Scalemic Vinyl Oxazoles Followed by Oxazaenolate Alkylation**

Asymmetric coupling of aromatic Grignard reagents with scalemic aryl oxazolines has also been used to synthesize scalemic biphenyl compounds. In their initial paper on the synthesis of scalemic biphenyls, Meyers and Himmelsbach reported the reaction of various 2-substituted Grignard reagents with 2-(methoxyphenyl)oxazolines in THF resulting in the formation of biphenyl compounds with up to 92% diastereoselectivity (Table 19).<sup>63</sup> Use of aryllithium instead of Grignard reagents results in nonstereoselective coupling. The oxazoline group must be removed under conditions mild enough to avoid racemization of the biphenyl.

This coupling reaction was used strategically to form the scalemic biphenyl portion of steganone (84, Scheme 16).<sup>64</sup> Tetramethoxyphenyl oxazoline 83, formed in five steps from 3,4,5-trimethoxybenzoic acid, reacts first with the Grignard to give 65% and 9% of the two diastereomeric biphenyls. Removal of the acetal and then the oxazoline rings was done under highly controlled conditions in order to avoid racemization.

A similar approach was used to synthesize (-)-schi-zandrin (86) and (-)-isoschi-zandrin (87; Scheme 17).<sup>65</sup>

Table 19. Diastereoselective Conjugate Addition of Aryl Grignard Reagents with Scalemic Methoxyaryl Oxazolines

| entry | Grignard  | oxazoline   | % yield | % de | R/S | ref |
|-------|---|---|---------|------|-----|-----|
| 1     |    |    | 56      | 90   | R   | 61  |
| 2     |    |   | 43      | 87   | S   |     |
| 3     |    |   | 65      | 96   | R   |     |
| 4     |    |    | 59      | 36   |     | 63  |
| 5     |    |   | 72      | 92   |     |     |
| 6     |    |    | 75      | 60   |     |     |
| 7     |    |   | 85      | 0    |     |     |
| 8     |    |   | 85      | 58   |     |     |
| 9     |   |   | 95      | 68   |     |     |
| 10    |  |  | 74      | 76   |     | 64  |
| 11    |  |   | 53      | 47   | S   |     |
| 12    | R = 2-(1,3-dioxanyl)  |   | 60      | 100  |     |     |
| 13    | R = 2-(1,3-dithianyl)   |   | 40      | 47   | S   |     |
| 14    | R = CH <sub>2</sub> OCH <sub>3</sub>  |   | 68      | 72   | S   | 65  |
| 15    | R = CH <sub>2</sub> OTBS  |   | 52      | 73   | S   |     |
| 16    | R = CH <sub>3</sub>   |   | 26      | 68   | R   |     |
| 17    | R = CH <sub>2</sub> OH  |   | 56      | 56   | S   | 66  |
|       | R = CH <sub>2</sub> OCH <sub>3</sub>  |  |         |      |     |     |
| 18    | R = CH <sub>3</sub>   |   | 80      | 80   | S   |     |
| 19    | R = CH <sub>2</sub> OSiMe <sub>2</sub> - <i>t</i> -Bu                               |   | 90      | 96   | S   |     |
| 20    | R = CH <sub>2</sub> OH  |   | 16      | 90   | R   |     |
| 21    | R = CH <sub>2</sub> OCH <sub>3</sub>  |  | 9       | 50   | S   |     |
| 22    | R = CH <sub>3</sub>   |   | 75      | 82   | S   |     |
| 23    | R = CH <sub>2</sub> OSiMe <sub>2</sub> - <i>t</i> -Bu                               |   | 60      | 0.96 | S   |     |

Meyers, Meier, and Rawson recently reported that oxazolines formed from valinol and *tert*-leucinol also react with high diastereoselectivities in this reaction.<sup>66</sup>

Meyers and co-workers also developed similar reactions involving the diastereoselective addition of organolithium and Grignard reagents to scalemic 3-







Figure 9.

## Scheme 16. Enantioselective Synthesis of (-)-Steganone



pyridyloxazolines (Table 21, entries 1–6).<sup>67</sup> They found that addition of organolithium or organomagnesium reagents to chiral 3-pyridyloxazoline followed by

## Scheme 17. Enantioselective Synthesis of (-)-Schizandrin and Isoschizandrin





Table 20. Diastereoselective Coupling of Scalemic 1-Alkoxy-2-naphthoxazolines with Naphthyl Grignards

| entry | R                | OR*                | % yield | % ee | R/S      |
|-------|------------------|--------------------|---------|------|----------|
| 1     | H                | <i>l</i> -menthoxy | 80      | 67   | <i>S</i> |
| 2     |                  | quininoxy          | 12      | 80   | <i>S</i> |
| 3     |                  | quinidyl           | 15      | 81   | <i>R</i> |
| 4     |                  | $\alpha$ -fenchyl  | 78      | 45   | <i>S</i> |
| 5     |                  | boronoxy           | 83      | 10   | <i>R</i> |
| 6     | OCH <sub>3</sub> | <i>l</i> -menthoxy | 53      | 78   | <i>S</i> |
| 7     |                  | quininoxy          | 7       | 94   | <i>R</i> |
| 8     |                  | quinidinoxy        | 27      | 84   | <i>S</i> |
| 9     |                  | $\alpha$ -fencoxy  | 65      | 48   | <i>S</i> |

quenching with methyl chloroformate gives 4-substituted 1,4-dihydro pyridine derivatives with high diastereoselectivity. Similar results are obtained in the reaction of MeLi with a scalemic 3-quinolyloxazoline 88 to give 89 (eq 16). A similar protocol was used by




Mangeny and coworkers (Table 21, entries 7–18).<sup>68</sup> A scalemic aminor, readily obtained from 3-pyridine-3-carboxaldehyde, was used rather than an oxazoline. Cuprate reagents in THF are used to add the allyl substituent to the pyridine ring. The reaction is performed in the presence of an acyl chloride trapping reagent. Diastereoselectivities as high as 95% are obtained. 1,6-Addition product is obtained when cuprate reagents are used in ether or when a Grignard reagent is used in THF. This method has been used in the synthesis of indoloquinolizidines 92 (Scheme 18).<sup>69</sup>

Table 21. Diastereoselective Conjugate Addition to Scalemic 3-Pyridyl Oxazolines and Imidizolidines

| entry | X | RM                                      | R <sub>1</sub>  | solvent | % yield | % de | R/S | ref |
|-------|---|---|-----------------|---------|---------|------|-----|-----|
| 1     |   | MeLi                                    | OMe             | THF     | 79      | 88   | S   | 67  |
| 2     |   | MeMgCl                                  |                 |         | 88      | 82   | S   |     |
| 3     |   | <i>n</i> -BuLi                          |                 |         | 92      | 86   | S   |     |
| 4     |   | <i>n</i> -BuMgCl                        |                 |         | 98      | 90   | S   |     |
| 5     |   | EtMgBr                                  |                 |         | 63      | 84   | S   |     |
| 6     |   | PhLi                                    |                 |         | 94      | 84   | S   |     |
| 7     |   | MeLi                                    | CH <sub>3</sub> | ether   | -       | -    | -   | 68  |
| 8     |   | MeMgBr                                  |                 | THF     | 10      | 93   | R   |     |
| 9     |   | Me <sub>2</sub> CuLi                    |                 | ether   | 56      | 95   | R   |     |
| 10    |   |   |                 | THF     | 90      | 41   | R   |     |
| 11    |   | Me <sub>2</sub> CuMgBr                  |                 |         | 90      | 95   | R   |     |
| 12    |   | Et <sub>2</sub> CuLi                    |                 | ether   | 64      | 32   | R   |     |
| 13    |   | Et <sub>2</sub> CuMgBr                  |                 | THF     | 90      | 82   | R   |     |
| 14    |   | Et <sub>2</sub> CuLi                    |                 |         | 90      | 85   | R   |     |
| 15    |   | <i>n</i> -Bu <sub>2</sub> CuLi          |                 |         | 40      | 95   | R   |     |
| 16    |   | (CH <sub>2</sub> =CH) <sub>2</sub> CuLi |                 |         | 90      | 95   | R   |     |
| 17    |   | Ph <sub>2</sub> CuMgBr                  |                 |         | 90      | 95   | R   |     |
| 18    |   | EtCu, 2LiBr                             |                 |         | 80      | 95   | R   | 69  |

Scheme 18. Enantioselective Synthesis of Indoloquinolizidines



Scheme 19. Diastereoselective Conjugate Addition of Organolithiums to Scalemic Naphthyl Oxazolines





Table 22. Diastereoselective Conjugate Addition to Scalemic Naphthyl Oxazolines

| entry | naphthalene           | OXZ | RLi  | E                    | % yield | % de | ref |
|-------|-----------------------|-----|--|----------------------|---------|------|-----|
| 1     | 1-naphthyl            | 73  | <i>n</i> -BuLi   | MeI                  | 97      | 88   | 70  |
| 2     |                       |     |  | (PhS) <sub>2</sub>   | 91      | 88   |     |
| 3     |                       |     |  | ClCO <sub>2</sub> Me | 99      | 94   |     |
| 4     |                       |     | MeLi   | (PhS) <sub>2</sub>   | 56      | 72   |     |
| 5     |                       |     | <i>t</i> -BuLi   | MeI                  | 98      | 48   |     |
| 6     |                       |     | PhLi   |                      | 99      | 66   |     |
| 7     |                       |     | (H <sub>2</sub> C=CMeCH <sub>2</sub> )Li                 |                      | 75      | 76   |     |
| 8     |                       |     | (H <sub>2</sub> C=CH)Li                                  |                      | 79      | 80   |     |
| 9     |                       |     | ( <i>c</i> -1-C <sub>5</sub> H <sub>7</sub> )Li          |                      | 73      | 78   |     |
| 10    |                       |     | (Me <sub>3</sub> Si)Li                                   |                      | 70      | 20   |     |
| 11    |                       |     | EtLi   |                      | 92      | 88   |     |
| 12    | 1-(5-methoxynaphthyl) |     | (H <sub>2</sub> C=CH)Li                                  |                      | 80      | 60   |     |
| 13    |                       |     | [H <sub>2</sub> C=CH(CH <sub>2</sub> ) <sub>3</sub> ]Li  |                      | 80      | 90   |     |
| 14    |                       |     | <i>n</i> -BuLi   |                      | 95      | 94   |     |
| 15    | 1-(6-methoxynaphthyl) |     | ( <i>c</i> -1-C <sub>5</sub> H <sub>7</sub> )Li          |                      | 50      | 70   |     |
| 16    | 1-(4-methoxynaphthyl) |     | <i>n</i> -BuLi   |                      | 95      | 94   |     |
| 17    |                       |     | <i>t</i> -BuLi   |                      | 95      | 30   |     |
| 18    |                       |     | [H <sub>2</sub> C=CH(CH <sub>2</sub> ) <sub>3</sub> ]Li  |                      | 90      | 94   |     |
| 19    |                       |     | [H <sub>2</sub> C=CMe(CH <sub>2</sub> ) <sub>3</sub> ]Li |                      | 90      | 94   |     |
| 20    | 2-naphthyl            |     | PhLi   |                      | 89      | 80   |     |
| 21    |                       |     | <i>n</i> -BuLi   |                      | 85      | 96   |     |
| 22    |                       | 95  | PhLi   |                      | 90      | 82   |     |
| 23    |                       |     | <i>n</i> -BuLi   |                      | 87      | 88   |     |
| 24    |                       | 96  | PhLi   |                      | 93      | 50   |     |
| 25    |                       | 97  |  |                      | 90      | 82   |     |
| 26    |                       |     | <i>n</i> -BuLi   |                      | 96      | 86   |     |
| 27    | 1-naphthyl            | 73  |  |                      | 100     | 88   |     |
| 28    |                       | 97  |  |                      | 93      | 84   |     |
| 29    |                       | 73  | PhLi   |                      | 100     | 72   |     |
| 30    |                       | 96  |  |                      | 94      | 40   |     |
| 31    |                       | 98  | <i>n</i> -BuLi   |                      | 97      | 94   | 71  |
| 32    |                       |     | (H <sub>2</sub> C=CH)Li                                  |                      | 89      | 88   |     |
| 33    |                       |     | PhLi   |                      | 87      | 74   |     |
| 34    |                       | 74  | <i>n</i> -BuLi   |                      | 99      | 98   |     |
| 35    |                       |     | (H <sub>2</sub> C=CH)Li                                  |                      | 94      | 98   |     |
| 36    |                       |     | PhLi   |                      | 81      | 90   |     |

<sup>a</sup> OXZ as follows:



In a further extension of this work, Meyers and co-workers have developed an interesting set of protocols for DCA to scalemic naphthyloxazolines (Scheme 19).<sup>70</sup> Reaction of organolithium reagents with scalemic naphthyloxazolines **93** results in addition to the naphthyl ring with high diastereoselectivity to give **94**. The intermediate thus formed can be treated with an electrophile to give  $\alpha$  substitution or with trifluoroacetic acid to protonate the aza enolate. Treatment with an electrophile gives exclusively a substitution pattern in which the R group and the oxazoline group are *cis* to one another (Table 22). In contrast, treatment with trifluoroacetic acid gives a product in which the R group and the oxazoline are *trans* to one another (Table 23). The diastereoselectivity is controlled similar to that shown above for vinyl oxazolines.





Rawson and Meyers recently reported that excellent levels of diastereoselectivity can be achieved in similar systems using valinol or *tert*-leucinol to form the oxazolines (Table 22, entries 31–36).<sup>71</sup> The *tert*-leucinol system in particular gives the best results seen thus far and is viewed by the authors as the system of choice.

Table 23. Diastereoselective Conjugate Addition to Scalemic Naphthyl Oxazolines

| entry | naphthalene           | RLi            | E   | % yield | % de |
|-------|-----------------------|----------------|-----|---------|------|
| 1     | 1-naphthyl            | <i>n</i> -BuLi | TFA | 73      | 88   |
| 2     |                       | PhLi           |     | 62      | 70   |
| 3     |                       | MeLi           |     | 42      | 70   |
| 4     | 1-(5-methoxynaphthyl) | EtLi           |     | 85      | 94   |
| 5     |                       | <i>i</i> -PrLi |     | 73      | 92   |

Unfortunately, the amino alcohol currently is expensive. Valinol, however, is readily available either commercially or by synthesis.

This method has been used in the synthesis of a number of natural products including (–)-podophyllotoxin (**106**; Scheme 20),<sup>72</sup> (+)-phyltetralin (**102**; Scheme 21),<sup>70a</sup> the A–B ring of alkavinone (**104**; Scheme 22),<sup>73</sup> and analogues to the bottom half of chlorothricolide

**Scheme 20. Synthesis of Podophyllotoxin****Scheme 21. Synthesis of (+)-Phyltetralin****Scheme 22. Synthesis of the A-B Ring of Aklavinone****Scheme 23. Synthesis of Analogues of Chlorothricolide**

106–109 (Scheme 23)<sup>74</sup> and tetracyclic terpene ring systems related to aphidicolin, scopadulcic acid, and kauranes (Scheme 24).<sup>75</sup>

This method can also be used to form the polycyclic compounds 113 by DCA followed by internal alkylation (Scheme 25).<sup>76</sup>

**G.  $\alpha,\beta$ -Unsaturated Aldimines**

Enantiomerically enriched  $\beta,\beta$ -disubstituted aldehydes have been synthesized by reacting Grignard reagents with scalemic  $\alpha,\beta$ -unsaturated aldimines derived from  $\alpha,\beta$ -unsaturated aldehydes and scalemic  $\alpha$ -amino acid esters (Table 24).<sup>77</sup> The mechanism is believed to involve initial chelation of the imine nitrogen and ester oxygen with the magnesium followed by addition of the R group to the bottom face of the olefin (Figure 10).

This method was also used in the synthesis of scalemic 2-substituted cycloalkanecarbaldehydes<sup>78</sup> (Table 25) including the natural product (+)-ivalin (115) from 114 (Scheme 26).<sup>79</sup>




DCA followed by alkylation of the intermediate enamine gave the 1,2-disubstituted cycloalkane carbaldehyde (Table 26).<sup>80</sup> The stereochemical course of the reaction depends on the method used to carry out the reaction.

Meyers, Brown, and Laucher were able to perform similar additions of organolithiums to scalemic naph-


thyl aldimines 116 (Scheme 27).<sup>81</sup> The stereochemical outcome of these reactions was rationalized by assuming the organolithium and the naphthyl aldimine form a complex as shown, followed by transfer of the R group to the underside of the naphthyl ring (Figure 11).

**III. Enantioselective Conjugate Addition of Organometallics to Prochiral  $\alpha,\beta$ -Unsaturated Ketones****A. Scalemic Lithium Organo(alkoxo)cuprates**

Among the early attempts to form enantioselective chiral cuprate reagents were those which involved formation of mixed cuprates derived from a chiral alcohol and an organolithium or magnesium reagent (Table 27). Initial attempts at making chiral mixed cuprates from chiral alcohols involved the use of 1,2:5,6-di-*O*-isopropylidene- $\alpha$ -D-glycofuranose (2),<sup>82</sup> (*S*)-prolinol (125),<sup>83</sup> cinchonidine (131),<sup>84</sup> (*R*)-(2,4,6-trimethoxybenzylidene)phenylglycinol (134), and (*R*)-2-


**Scheme 24. Enantioselective Synthesis of Tetracyclic Terpene Ring Systems Related to Aphidicolin, Scopadulcic Acid, and Kauranes**

**Scheme 25. Diastereoselective Conjugate Addition to Naphthyl Oxazoline Followed by Internal Alkylation**

**Table 24. Diastereoselective Conjugate Addition to  $\alpha,\beta$ -Unsaturated Aldimines of Optically Active  $\alpha$ -Amino Acid Esters**


| entry | R  | R <sub>1</sub> | R <sub>2</sub> -M  | solvent           | % yield | % ee | R/S      |
|-------|----|----------------|--|-------------------|---------|------|----------|
| 1     | Me | <i>i</i> -Pr   | PhMgBr   | ether             | 11      | 67   | <i>R</i> |
| 2     |    |                |  | THF               | 55      | 53   |          |
| 3     |    |                |  | THF-ether (5:1)   | 53      | 57   |          |
| 4     |    |                |  | ether-THF (5:1)   | 49      | 65   |          |
| 5     |    |                |  | toluene-THF (6:1) | 36      | 49   |          |
| 6     |    |                |  | hexane-THF (3:1)  | 38      | 44   |          |
| 7     |    |                | Ph <sub>2</sub> Mg   | ether             | 31      | 67   |          |
| 8     |    |                |  | THF               | 64      | 52   |          |
| 9     |    |                | PhMgBr-CuI   | ether             | 12      | 65   |          |
| 10    |    |                |  | THF               | 64      | 52   |          |
| 11    |    |                | PhMgBr   | ether-THF (5:1)   | 42      | 65   |          |
| 12    |    |                | <i>c</i> -C <sub>8</sub> H <sub>11</sub> Br                                |                   | 6       | 71   |          |
| 13    |    | <i>t</i> -Bu   | PhMgBr   |                   | 52      | 91   |          |
| 14    |    |                | <i>c</i> -C <sub>8</sub> H <sub>11</sub> MgBr                              |                   | 53      | 96   |          |
| 15    |    |                | <i>n</i> -BuMgBr   |                   | 40      | 98   | <i>S</i> |
| 16    |    |                | [(CH <sub>3</sub> ) <sub>2</sub> C=CH(CH <sub>2</sub> ) <sub>2</sub> ]MgBr |                   | 48      | 98   | <i>R</i> |
| 17    | Ph |                | EtMgBr   |                   | 56      | 95   | <i>S</i> |

**Table 25. Diastereoselective Conjugate Addition to Scalemic Cyclic Aldimines**


| entry | <i>n</i> | R            | R <sub>1</sub>      | % yield | % ee |
|-------|----------|--------------|---------------------|---------|------|
| 1     | 5        | <i>i</i> -Pr | Ph                  | 72      | 61   |
| 2     |          | <i>t</i> -Bu |                     | 82      | 82   |
| 3     |          | <i>i</i> -Pr | CH <sub>2</sub> =CH | 36      | 71   |
| 4     |          | <i>t</i> -Bu |                     | 69      | 92   |
| 5     | 6        | <i>i</i> -Pr | Ph                  | 52      | 49   |
| 6     |          | <i>t</i> -Bu |                     | 54      | 91   |
| 7     |          | <i>i</i> -Pr | CH <sub>2</sub> =CH | 31      | 69   |
| 8     |          | <i>t</i> -Bu |                     | 68      | 93   |

butanol (119).<sup>85</sup> In all cases, the ee's observed were well below 50%. Imamoto and Mukaiyama reported the use of a cuprate formed from *N*-methylprolinol (126) and MeMgBr which, when reacted with chalcone, gives the expected product in  $\leq 68\%$  ee.<sup>86</sup>



**Figure 10.**
**Scheme 26. Enantioselective Synthesis of (+)-Ivalin**


Leyendecker et al. used derivatives of proline as cuprate ligands for ECA to several ketones and obtained ee's as high as 88%.<sup>87</sup> Analogues of these ligands, 127-

Table 26. Diastereoselective Synthesis of 1,2-Disubstituted Cycloalkanecarboxaldehydes

| entry | method | n | R                   | R <sub>1</sub> X                      | % yield |       | % ee |
|-------|--------|---|---------------------|---------------------------------------|---------|-------|------|
|       |        |   |                     |                                       | cis     | trans |      |
| 1     | A      | 5 | Ph                  | CH <sub>3</sub> I                     | 65      | 0     | 82   |
| 2     |        |   | CH <sub>2</sub> =CH |                                       | 61      | 0     | 92   |
| 3     |        | 6 | Ph                  |                                       | 62      | 1     | 91   |
| 4     |        |   | CH <sub>2</sub> =CH |                                       | 51      | 11    | 93   |
| 5     | B      | 5 | Ph                  |                                       | 62      | 15    | 82   |
| 6     |        |   | CH <sub>2</sub> =CH |                                       | 0       | 62    | 92   |
| 7     |        | 6 | Ph                  |                                       | 0       | 55    | 91   |
| 8     |        |   | CH <sub>2</sub> =CH |                                       | 0       | 67    | 93   |
| 9     |        |   |                     | PhCH <sub>2</sub> I                   | 0       | 67    | 93   |
| 10    |        |   |                     | CH <sub>2</sub> =CHCH <sub>2</sub> Br | 0       | 63    | 93   |
| 11    |        |   |                     | C <sub>2</sub> H <sub>5</sub> I       | 0       | 65    | 93   |
| 12    |        |   |                     | CH <sub>3</sub> OCH <sub>2</sub> Cl   | 0       | 52    | 93   |
| 13    | C      | 5 | Ph                  | CH <sub>3</sub> I                     | 44      | 2     | 82   |
| 14    |        | 6 |                     |                                       | 49      | 0     | 91   |

Scheme 27. Diastereoselective Conjugate Addition to Scalemic Naphthyl Imines



| R            | 113     |      | 114     |      |
|--------------|---------|------|---------|------|
|              | % Yield | % ee | % Yield | % ee |
| <i>i</i> -Pr | 78      | 95   | -       | -    |
| <i>n</i> -Bu | 78      | 95   | 85      | 95   |
| <i>t</i> -Bu | 85      | 95   | 75      | 95   |

129, give poor ee's. Corey, Naef, and Hannon reported a chiral mixed cuprate,  $\text{LiCu}(\text{OR}^*)\text{R}_1$  in which  $\text{HOR}^*$  is one of two diamino alcohols, 137 and 138, which were derived from (1*R*,2*S*)-(-)-ephedrine and (*R*)-mandelic acid, respectively.<sup>88</sup> The cuprate reagent is formed by deprotonating the alcohol with an alkyllithium reagent, reacting this alkoxide with  $\text{CuI}$  in THF/dimethyl sulfide to form the copper alkoxide, and adding an additional 1 equiv of the alkyl lithium to form the reagent. The reaction is performed at  $-78^\circ\text{C}$  by adding the enone neat to the reaction mixture. The use of even slightly contaminated alkyllithium reagents results in lower ee's. In order to rectify this situation, a modified protocol was developed in which MeI is added to the reaction mixture in order to react with alkoxides presumed to be present as contaminants in old bottles of alkyllithium reagents.

A mechanism was proposed to account for the enantioselectivity observed in this reaction (Figure 12). As shown, the cuprate is represented as a monomer in which one lithium is coordinated to the ligand through the






Figure 11.

alkoxide oxygen and two nitrogen atoms and the copper is bridging between the alkoxide oxygen and the alkyl group, R. An additional lithium ion tethers the enone through the carbonyl oxygen to the alkoxide oxygen. This model suggests the predominant enantiomer in this reaction will be *R*.

Tanaka, Ushio, and Suzuki recently reported the use of 10 chiral amino alcohols, 140–149, for use as chiral cuprate alkoxide ligands.<sup>89</sup> The ligands were used to form chiral methyl (alkoxy) cuprates and then reacted with (*E*)-2-cyclopentadecenone to form enantiomerically enriched Muscone (eq 17). They later reported that the enantioselectivity of this reaction, using ligands 144 and 149, can be improved by forming the reagent in toluene with 2–10 equiv of THF. In each case products of 100% ee, as determined by optical rotation, are obtained.<sup>90</sup>



Other scalemic alcohols and amino alcohols have been used by several groups but without great success.<sup>91,92</sup>



S = THF; X = I or THF

**Figure 12.** Proposed intermediate in conjugate addition with Corey's cuprate.

## B. Scalemic Lithium Organo(amido)cuprates

A number of research groups have looked at the use of chiral lithium organo(amido)cuprates as agents for ECA to enones, particularly cyclic enones (Table 28). Bertz, Dabbagh, and Sundararajan formed mixed cuprates with phenyl as the transferable ligand and chiral primary amides as the nontransferable ligand and reacted them with 2-cyclohexenone (entries 1–50).<sup>91</sup> Enantioselectivities as high as 50% were reported.

Dieter and Tokles reported the use of four derivatives of proline, 198–201, as chiral auxiliaries in organo(amido)cuprates (entries 51–111).<sup>93</sup> Enantiomeric excesses as high as 83% were attained in a survey that included several enones as well as the above-mentioned nontransferable ligands. They later reported some difficulties in reproducing their work and extended their original investigation to include other chiral ligands.<sup>94</sup>

In order to explain the enantioselectivity observed, they suggest the lithium organo(amido)cuprate forms a dimeric complex, with the organo and amido ligands occupying alternating bridging positions (Figure 13). They further suggest that the second chelating group (OMe, NC<sub>4</sub>H<sub>8</sub>, SMe, or SPh) occupies a ligand site in the lithium coordination sphere. The structures thus formed possess C<sub>2</sub> symmetry. The enone complexes to the cuprate either through a lithium–oxygen complex or a copper–olefin complex or both. The alkyl group is transferred to the face of the olefin coordinated to the copper atom. They assume preferential conjugate addition with the complex which gives the *S* isomer. The cuprate derived from ligand 198 has been used in the synthesis of (+)-confertin (Scheme 28).<sup>95</sup>

Rossiter and Eguchi reported a study in which a series of 11 chiral secondary amines, 168, 171, 173, 184, 207, 208, and 211–215, were screened as chiral nontransferable cuprate ligands in the conjugate addition of *n*-butyl to 2-cyclohexenone (entries 112–166).<sup>96</sup> The structures of the chiral ligands were based on 1-phenylethylamine. The structure of this ligand was modified systematically in order to discern relationships between the structures of the ligands and the enantioselectivity of the reaction. Of the ligands screened, ligand 208 proved to be the most successful, giving 3-*n*-butylcyclohexanone in 83% ee and up to 92% yield and 3-phenylcyclohexanone in 97% ee. The cuprate formed using ligand 208 was reacted with cyclic enones of ring sizes 5–8 in order to discern the overall selectivity of this reagent with other substrates.<sup>97</sup> The enantioselectivity with this series of enones increased, going from cyclopentenone to cycloheptenone, and then dropped with cyclooctenone. Reaction with cyclohep-

tenone using either methyl or butyl as the transferable ligand gives product in 97% ee.

Enantioselectivity in the reactions using ligand 208 was rationalized by first assuming the amidocuprate forms a dimeric complex similar to that proposed by Dieter and Tokles (Figure 14). According to this model, the complex assumes a configuration in which both *N*-methyl groups point up relative to the plane of the complex. The piperidine groups bind to the lithium atoms and are positioned roughly where a solvent molecule would normally reside. The phenyl groups reside under the plane of the complex blocking its underside from interaction with the enone. The enone binds to one of the lithium atoms followed by interaction of the olefin with one of the copper atoms. This positions the enone directly over the stereochemically accessible side of the complex in order to obtain best orbital overlap and to avoid undesirable stereochemical interactions with the two *N*-alkyl groups. When the *re* face of the enone complexes with cuprate, the hydrogens on the 4, 5, and 6 carbons of the cyclohexenone interact unfavorably with one of the methyl groups pointing out of the plane of the complex, making this a relatively high energy complex. When the *si* face of the enone interacts with the cuprate, the same hydrogens will point toward the more stereochemically open corner of the complex. This model predicts the *S* enantiomer will be formed preferentially with the *S* ligand in conformance with experimental observation. Rossiter and co-workers also reported asymmetric amplification with this cuprate.<sup>98</sup> Cuprate formed with ligand of 56% ee and with *n*-butyl as the transferable ligand was reacted with 2-cycloheptenone to give 3-*n*-butylcycloheptanone in 81% ee.

Lippard and co-workers recently described a copper(I) complex capable of catalyzing the conjugate addition of Grignard reagents to enones with up to 78% ee and moderate to high chemical yields (Table 29).<sup>99</sup> These complexes consist of copper(I) bound to the chiral aminotroponone imines H(*R*-CHIRAMPT) (222) and H(*R*-NEAT) (221). They found the enantioselectivity of these reactions is significantly increased by running them in the presence of HMPA and silyl chlorides. For example, reaction of *n*-BuMgCl with 2-cyclohexenone in the presence of 2 equiv of HMPA and Ph<sub>2</sub>(*t*-Bu)SiCl and 0.037 equiv of Cu[*R*-CHIRAMPT] gives 3-*n*-butylcyclohexanone in 53% yield and 74% ee. Slightly higher ee's are obtained when a stoichiometric amount of the catalyst is used. An X-ray structure of the chiral copper complex has been obtained.<sup>100</sup>

## C. Scalemic Lithium Diorganocuprates

Several groups have used scalemic cuprate reagents in which one of the ligands is (*S*)-2-[1-(dimethylamino)ethyl]phenyl or (*S*)-2-[cyclohexyl(dimethylamino)methyl]phenyl. Andersson et al. found that reaction of [(*S*)-2-[1-(dimethylamino)ethyl]phenyl](2-thienyl)copperlithium with 4-phenyl-3-buten-2-one, 2-cyclohexenone, and 2-cyclopentenone in each case gave the *S* product in which the scalemic ligand was transferred.<sup>101</sup> In the case of 2-cyclopentenone, conjugate addition occurred with 84% diastereoselectivity (eq 18). Gustafsson<sup>102</sup> and Malmberg and Nilsson performed similar experiments, but with cuprates in which the achiral ligand was transferred (eq 19).

Table 27. Enantioselective Conjugate Addition to Enones with Scalemic Organo(alkoxo)cuprates,  $\text{MCu}(\text{OR}^*)\text{R}$ 

$$\text{R}^*\text{OLi} + \text{RCu} \longrightarrow \text{"LiCu}(\text{OR}^*)\text{R"} \xrightarrow[\text{2. H}_3\text{O}^+]{\text{1. } \text{Cyclohex-2-en-1-one}} \text{Cyclohex-2-en-1-yl-R}$$


| entry           | substrate                          | HOR* <sup>d</sup> | RM                              | solvent       | % yield | % ee    | R/S | ref |
|-----------------|------------------------------------|-------------------|---------------------------------|---------------|---------|---------|-----|-----|
| 1               | 2-cyclohexenone                    | 2                 | MeLi                            | ether         | NG      | [-0.93] | S   | 82  |
| 2               |                                    |                   | <i>n</i> -BuLi                  |               | NG      | [-0.8]  | ND  |     |
| 3               |                                    |                   | PhLi                            |               | NG      | [+0.42] | ND  |     |
| 4               |                                    | 125               | MeLi                            |               | NG      | 16      | S   | 83  |
| 5               | 1,3-diphenylpropenone              | 122               |                                 |               | 44      | 3       | S   | 84  |
| 6               |                                    | 123               |                                 |               | 59      | 2       | S   |     |
| 7               |                                    | 124               |                                 |               | 35      | 0       | -   |     |
| 8               |                                    | 130               |                                 |               | 21      | 34      | S   |     |
| 9               |                                    | 131               |                                 |               | 8       | 0       | -   |     |
| 10              |                                    | 132               | MeMgBr                          | THF           | 35      | 4       | R   |     |
| 11              |                                    | 133               | MeLi                            | ether         | 59      | 15      | S   |     |
| 12              |                                    |                   | MeMgBr                          | THF           | 23      | 25      | S   |     |
| 13              |                                    | 134               | MeLi                            | ether         | 17      | 31      | S   |     |
| 14              |                                    |                   | MeMgBr                          | THF           | 30      | 0       | -   |     |
| 15              |                                    | 135               | MeLi                            | ether         | 75      | 12      | R   |     |
| 16              | 2-cyclohexenone                    | 119               | <i>n</i> -BuLi                  |               | 48      | 6       | ND  | 85  |
| 17              | 4-phenyl-3-buten-2-one             |                   |                                 |               | 65      | [-4.4]  | ND  |     |
| 18              |                                    | 120               |                                 |               | 70      | [-3.0]  | ND  |     |
| 19              | 2-cyclohexenone                    | 4                 |                                 | THF           | 42      | 4       | ND  |     |
| 20              |                                    | 121               |                                 |               | 54      | 8       | ND  |     |
| 21              | ( <i>E</i> )-1,3-diphenylpropenone | 126               | MeMgBr                          |               | 88      | 61      | S   | 86  |
| 22              | ( <i>Z</i> )-1,3-diphenylpropenone |                   |                                 |               | 71      | 68      | S   |     |
| 23              | 2-cyclohexenone                    | 125               |                                 | benzene       | 61      | 26      | S   | 87a |
| 24              |                                    |                   |                                 | THF           | 85      | 6       | S   |     |
| 25              | 1,3-diphenylpropenone              |                   |                                 |               | 70      | 15      | S   |     |
| 26              |                                    |                   |                                 | toluene       | 42      | 20      | S   |     |
| 27              | 4-phenyl-3-butenone                |                   |                                 | THF           | 61      | 29      | S   |     |
| 28              |                                    |                   |                                 | toluene       | 36      | 37      | S   |     |
| 29              | 1,3-diphenylpropenone              | 126               |                                 |               | 32      | 2       | S   |     |
| 30              |                                    |                   |                                 | THF           | 81      | 41      | S   |     |
| 31              | 4-phenyl-3-buten-2-one             |                   |                                 | toluene       | 36      | 3       | R   |     |
| 32              |                                    |                   |                                 | THF           | 92      | 10      | S   |     |
| 33              | 2-cyclohexenone                    |                   |                                 | benzene       | 64      | 1       | R   |     |
| 34              |                                    |                   |                                 | THF           | 70      | 5       | R   |     |
| 35              | ( <i>E</i> )-1,3-diphenylpropenone | 127               |                                 |               | 55      | 7       | S   | 87b |
| 36              |                                    | 125               |                                 |               | 70      | 15      | S   |     |
| 37              |                                    | 126               |                                 |               | 80      | 88      | S   |     |
| 38              |                                    | 128               |                                 |               | 94      | 0       | -   |     |
| 39              |                                    | 129               |                                 |               | 86      | 2       | R   |     |
| 40              | 2-cyclopentenone                   | 137               | EtLi                            |               | 68      | 77      | R   | 88  |
| 41              |                                    |                   | <i>n</i> -BuLi                  |               | 60      | 72      | R   |     |
| 42              |                                    |                   | <i>t</i> -BuOCH <sub>2</sub> Li |               | 52      | 81      | R   |     |
| 43              | 2-cyclohexenone                    |                   | EtLi                            |               | 90      | 92      | R   |     |
| 44              |                                    |                   | <i>n</i> -BuLi                  |               | 90      | 89      | R   |     |
| 45              |                                    |                   | <i>t</i> -BuOCH <sub>2</sub> Li |               | 73      | 85      | R   |     |
| 46              |                                    | 138               | MeLi                            | ether/toluene | 60      | 90      | R   |     |
| 47              |                                    | 139               | <i>n</i> -BuLi                  | THF           | 68      | 16      | R   | 92  |
| 48              |                                    | 140               |                                 |               | 63      | 14      | R   |     |
| 49              |                                    | 141               |                                 |               | 68      | 15      | R   |     |
| 50              | ( <i>E</i> )-2-cyclopentadecenone  | 142               |                                 | toluene       | 82      | 49      | S   | 89  |
| 51              |                                    | 143               |                                 |               | 72      | 39      | S   |     |
| 52              |                                    | 144               |                                 | toluene/THF   | 89      | 100     | S   | 90  |
| 53              |                                    | 145               |                                 | toluene       | 86      | 50      | S   | 89  |
| 54              |                                    | 146               |                                 |               | 90      | 33      | R   |     |
| 55              |                                    | 147               |                                 | toluene/THF   | 80      | 95      | R   | 90  |
| 56              |                                    | 148               |                                 | toluene       | 90      | 64      | R   | 89  |
| 57              |                                    | 149               |                                 | toluene/THF   | 90      | 100     | S   | 90  |
| 58              |                                    | 150               |                                 |               | 70      | 39      | R   | 89  |
| 59              |                                    | 151               |                                 |               | 59      | 15      | S   |     |
| 60              | 2-cyclohexenone                    | 124               | PhLi                            | ether         | 38      | 10      | R   | 91  |
| 61              |                                    | 125               |                                 |               | 52      | 10      | S   |     |
| 62              |                                    | 152               |                                 |               | 31      | 10      | R   |     |
| 63              |                                    | 153               |                                 |               | 53      | 0       | -   |     |
| 64              |                                    | 154               |                                 |               | 15      | 20      | R   |     |
| 65              |                                    | 155               |                                 |               | 37      | 10      | R   |     |
| 66              |                                    | 156               |                                 |               | 14      | 10      | R   |     |
| 67              |                                    | 157               |                                 |               | 94      | 50      | R   |     |
| 68 <sup>a</sup> |                                    |                   |                                 |               | 91      | 20      | R   |     |
| 69 <sup>b</sup> |                                    |                   |                                 |               | 48      | 40      | R   |     |
| 70 <sup>c</sup> |                                    |                   |                                 |               | 72      | 20      | R   |     |
| 71              |                                    |                   |                                 | THF           | 34      | 50      | R   |     |



Table 27. (Continued)

| entry           | substrate | HOR* <sup>d</sup> | RM     | solvent                        | % yield | % ee | R/S | ref |
|-----------------|-----------|-------------------|--------|--------------------------------|---------|------|-----|-----|
| 72 <sup>a</sup> |           |                   |        |                                | 46      | 10   | R   |     |
| 73 <sup>b</sup> |           |                   |        |                                | 39      | 50   | R   |     |
| 74 <sup>c</sup> |           |                   |        |                                | 38      | 0    | -   |     |
| 75              |           |                   |        | ether                          | 65      | 20   | R   |     |
| 76              |           |                   | PhMgBr |                                | 41      | 10   | S   |     |
| 77              |           |                   | PhLi   | THF                            | 39      | 50   | R   |     |
| 78              |           |                   | PhMgBr |                                | 7       | 50   | S   |     |
| 79              |           |                   | PhLi   | DME                            | 30      | 30   | R   |     |
| 80              |           |                   |        | ( <i>i</i> -Pr) <sub>2</sub> O | 45      | 20   | R   |     |
| 81              |           |                   |        | Me <sub>2</sub> O              | 39      | 0    | -   |     |
| 82              |           |                   |        | dioxane                        | 12      | 0    | -   |     |
| 83              |           |                   |        | Me <sub>2</sub> S              | 98      | 0    | -   |     |
| 84              |           | 158               |        | ether                          | 73      | 0    | -   |     |
| 85              |           | 159               |        |                                | 44      | 0    | -   |     |
| 86              |           | 160               |        |                                | 53      | 10   | R   |     |
| 87              |           | 161               |        |                                | 51      | 20   | R   |     |
| 88              |           | 162               |        |                                | 36      | 10   | R   |     |
| 89              |           | 163               |        |                                | 14      | 20   | R   |     |
| 90              |           | 164               |        |                                | 33      | 0    | -   |     |
| 91              |           | 165               |        |                                | 27      | 0    | -   |     |
| 92              |           | 166               |        |                                | 6       | 20   | S   |     |
| 93              |           | 167               |        |                                | 34      | 10   | R   |     |

<sup>a</sup> CuBr used. <sup>b</sup> CuOTf used. <sup>c</sup> CuCN used. <sup>d</sup> R\*OH =



Another approach to stereoselective conjugate addition involves the reaction of scalemic copper and zinc azaenolates with cyclic enones (Table 30).<sup>104</sup> The azaenolates are formed by reacting scalemic 1,2-amino ethers with acetone to form the imine, deprotonating at the  $\alpha$ -position of the imine with *n*-butyllithium, and treating this azaenolate with a copper salt or dimethyl zinc. Reaction of these complexes with 2-cyclopentenone and 2-cyclohexenone gives, after hydrolysis, 3-acetyl-cyclopentanone and 3-acetyl-cyclohexanone,





Figure 13.

respectively. This protocol was used in the synthesis of *trans*-dihydrindandione systems (Scheme 29).<sup>105</sup>

Table 28. Enantioselective Conjugate Addition to Enones with Chiral Organo(amido)cuprates,  $\text{LiCu}(\text{NR}^1\text{R}^2)\text{R}$ 

$\text{R}_1\text{R}_2\text{NLi} + \text{RCu} \longrightarrow \text{"LiCu}(\text{NR}_1\text{R}_2)\text{R"}$ 


| entry | ligand <sup>b</sup> | substrate            | R    | solvent           | CuX       | % yield | % ee | R/S         | ref |                        |    |    |   |
|-------|---------------------|----------------------|------|-------------------|-----------|---------|------|-------------|-----|------------------------|----|----|---|
| 1     | 168 (S)             | 2-cyclohexenone      | Ph   | ether             | CuI       | 69      | 30   | S           | 91  |                        |    |    |   |
| 2     |                     |                      |      |                   |           |         |      |             |     |                        | 12 | 30 | R |
| 3     | 168 (R)             |                      |      |                   |           |         |      |             |     |                        | 72 | 30 | R |
| 4     | 169 (R)             |                      |      |                   |           |         |      |             |     |                        | 62 | 40 | R |
| 5     |                     |                      |      |                   |           |         |      |             |     |                        | 72 | 30 | R |
| 6     |                     |                      |      |                   |           |         |      |             |     | CuBr                   | 47 | 40 | R |
| 7     |                     |                      |      |                   |           |         |      |             |     | CuOTf                  | 34 | 20 | R |
| 8     |                     |                      |      |                   |           |         |      |             |     | CuCN                   | 35 | 0  |   |
| 9     |                     |                      |      |                   |           |         |      |             |     | CuI/LiCN               | 54 | 40 | R |
| 10    |                     |                      |      |                   |           |         |      |             |     | CuCN/LiI               | 52 | 30 | R |
| 11    |                     |                      |      |                   |           |         |      |             |     | CuI/LiI                | 46 | 40 | R |
| 12    |                     |                      |      |                   |           |         |      |             |     | CuI/LiBPh <sub>4</sub> | 41 | 40 | R |
| 13    | 169 (S)             |                      |      |                   |           |         |      |             |     | CuI                    | 74 | 30 | S |
| 14    |                     |                      | a    |                   |           | 2       | 0    |             |     |                        |    |    |   |
| 15    |                     |                      |      | THF               |           | 6       | 10   | R           |     |                        |    |    |   |
| 16    |                     |                      | a    |                   |           | 11      | 10   | R           |     |                        |    |    |   |
| 17    |                     |                      |      | ether             |           | 78      | 20   | S (0 °C)    |     |                        |    |    |   |
| 18    |                     |                      |      |                   |           | 79      | 10   | S (25 °C)   |     |                        |    |    |   |
| 19    | 170                 |                      |      |                   |           | 50      | 40   | S           |     |                        |    |    |   |
| 20    | 175                 |                      |      |                   |           | 23      | 40   | R           |     |                        |    |    |   |
| 21    | 176                 |                      |      |                   |           | 74      | 0    |             |     |                        |    |    |   |
| 22    | 177                 |                      |      |                   |           | 88      | 10   | S           |     |                        |    |    |   |
| 23    | 178                 |                      |      |                   |           | 48      | 10   | S           |     |                        |    |    |   |
| 24    | 179                 |                      |      |                   |           | 86      | 20   | S           |     |                        |    |    |   |
| 25    | 180                 |                      |      |                   |           | 69      | 10   | S           |     |                        |    |    |   |
| 26    | 181                 |                      |      |                   |           | 42      | 0    |             |     |                        |    |    |   |
| 27    | 182                 |                      |      |                   |           | 31      | 30   | R           |     |                        |    |    |   |
| 28    | 183                 |                      |      |                   |           | 32      | 10   | S           |     |                        |    |    |   |
| 29    | 184 (S,S)           |                      |      |                   |           | 32      | 20   | R           |     |                        |    |    |   |
| 30    | 185                 |                      |      |                   |           | 34      | 40   | R           |     |                        |    |    |   |
| 31    | 186                 |                      |      |                   |           | 12      | 10   | R           |     |                        |    |    |   |
| 32    | 187                 |                      |      |                   |           | 49      | 10   | R           |     |                        |    |    |   |
| 33    |                     |                      |      | THF               |           | 22      | 60   | R           |     |                        |    |    |   |
| 34    | 188                 |                      |      | ether             |           | 62      | 50   | R           |     |                        |    |    |   |
| 35    |                     |                      | a    |                   |           | 29      | 10   | R           |     |                        |    |    |   |
| 36    |                     |                      |      | THF               |           | 26      | 0    |             |     |                        |    |    |   |
| 37    |                     |                      | a    |                   |           | 10      | 10   | R           |     |                        |    |    |   |
| 38    |                     |                      |      | hexane            |           | 51      | 30   | S           |     |                        |    |    |   |
| 39    |                     |                      |      | Me <sub>2</sub> S |           | 53      | 10   | R           |     |                        |    |    |   |
| 40    |                     |                      |      | Et <sub>2</sub> S |           | 56      | 0    |             |     |                        |    |    |   |
| 41    | 189                 |                      |      | ether             |           | 72      | 10   | R           |     |                        |    |    |   |
| 42    | 190                 |                      |      |                   |           | 66      | 10   | R           |     |                        |    |    |   |
| 43    | 191                 |                      |      |                   |           | 47      | 10   | S           |     |                        |    |    |   |
| 44    | 192                 |                      |      |                   |           | 59      | 10   | S           |     |                        |    |    |   |
| 45    | 193                 |                      |      |                   |           | 8       | 10   | S           |     |                        |    |    |   |
| 46    | 194                 |                      |      |                   |           | 24      | 50   | R           |     |                        |    |    |   |
| 47    | 195                 |                      |      |                   |           | 6       | 40   | R           |     |                        |    |    |   |
| 48    | 196                 |                      |      |                   |           | 47      | 10   | R           |     |                        |    |    |   |
| 49    | 197                 |                      |      |                   |           | 33      | 0    |             |     |                        |    |    |   |
| 50    | 198                 |                      |      |                   |           | 36      | 20   | R           |     |                        |    |    |   |
| 51    |                     |                      | Me   |                   | CuBr      | 77      | 82   | S (-25 °C)  | 93  |                        |    |    |   |
| 52    |                     |                      |      |                   | CuBr/LiBr | 35      | 63   | S           |     |                        |    |    |   |
| 53    |                     |                      |      |                   | CuBr      | 69      | 79   | S (-110 °C) |     |                        |    |    |   |
| 54    |                     |                      |      | THF               |           | 60      | 53   | R (-78 °C)  |     |                        |    |    |   |
| 55    |                     |                      |      | PhCH <sub>3</sub> |           | 63      | 70   | R           |     |                        |    |    |   |
| 56    |                     |                      |      | ether             | CuSCN     | 57      | 75   | R           |     |                        |    |    |   |
| 57    |                     |                      |      | PhCH <sub>3</sub> |           | 68      | 83   | R           |     |                        |    |    |   |
| 58    |                     |                      |      | ether             | CuBr      | 24      | 20   | R           |     |                        |    |    |   |
| 59    |                     | 2-cyclopentenone     |      |                   |           | 50      | 20   | S (-25 °C)  |     |                        |    |    |   |
| 60    |                     |                      |      |                   |           | 36      | 23   | S (-78 °C)  |     |                        |    |    |   |
| 61    |                     |                      |      | PhCH <sub>3</sub> |           | 70      | 37   | R           |     |                        |    |    |   |
| 62    |                     |                      |      | ether             | CuSCN     | 51      | 33   | R           |     |                        |    |    |   |
| 63    |                     |                      |      | PhCH <sub>3</sub> |           | 77      | 41   | S           |     |                        |    |    |   |
| 64    |                     |                      | t-Bu | ether             | CuBr      | 56      | 35   | S           |     |                        |    |    |   |
| 65    |                     | 2-cyclohexenone      | n-Bu |                   |           | 42      | 28   | S (-25 °C)  |     |                        |    |    |   |
| 66    |                     |                      | t-Bu |                   |           | 83      | 52   | S           |     |                        |    |    |   |
| 67    |                     |                      |      |                   |           | 25      | 67   | S (-78 °C)  |     |                        |    |    |   |
| 68    |                     | trans-3-penten-2-one | n-Bu |                   |           | 32      | 49   | S (-25 °C)  |     |                        |    |    |   |
| 69    |                     |                      |      |                   |           | 36      | 64   | S (-78 °C)  |     |                        |    |    |   |
| 70    |                     |                      |      | THF               |           | 62      | 38   | R           |     |                        |    |    |   |
| 71    |                     |                      |      | ether             | CuSCN     | 37      | 68   | R           |     |                        |    |    |   |


Table 28. (Continued)

| entry | ligand <sup>b</sup> | substrate                    | R            | solvent           | CuX                               | % yield | % ee | R/S      | ref |
|-------|---------------------|------------------------------|--------------|-------------------|-----------------------------------|---------|------|----------|-----|
| 72    |                     | <i>trans</i> -3-octen-2-one  | Me           |                   | CuBr                              | 46      | 58   | <i>R</i> |     |
| 73    |                     |                              |              |                   | CuSCN                             | 56      | 75   | <i>R</i> |     |
| 74    | 199                 | 2-cyclohexenone              | Me           | ether             | CuBr                              | 39      | 8    | <i>S</i> |     |
| 75    |                     | 2-cyclopentenone             |              |                   |                                   | 35      | 1    | <i>S</i> |     |
| 76    | 200                 |                              |              | PhCH <sub>3</sub> |                                   | 58      | 32   | <i>R</i> |     |
| 77    |                     |                              |              |                   |                                   | 60      | 35   | <i>R</i> |     |
| 78    |                     | 2-cyclohexenone              |              | THF               |                                   | 70      | 52   | <i>R</i> |     |
| 79    |                     |                              |              | ether             |                                   | 78      | 71   | <i>S</i> |     |
| 80    |                     |                              |              | PhCH <sub>3</sub> |                                   | 71      | 80   | <i>R</i> |     |
| 81    |                     | 2-cyclopentenone             | <i>t</i> -Bu | ether             |                                   | 50      | 50   | <i>S</i> |     |
| 82    |                     | <i>trans</i> -3-penten-2-one | <i>n</i> -Bu | THF               |                                   | 48      | 46   | <i>R</i> |     |
| 83    |                     |                              |              | ether             |                                   | 51      | 61   | <i>S</i> |     |
| 84    |                     | <i>trans</i> -3-octen-2-one  | Me           |                   |                                   | 42      | 74   | <i>R</i> |     |
| 85    | 201                 | 2-cyclohexenone              |              |                   |                                   | 68      | 80   | <i>S</i> |     |
| 86    |                     |                              | <i>n</i> -Bu |                   |                                   | 46      | 58   | <i>S</i> |     |
| 87    |                     |                              | <i>t</i> -Bu |                   |                                   | 51      | 69   | <i>S</i> |     |
| 88    |                     | 2-cyclopentenone             | Me           |                   |                                   | 60      | 33   | <i>S</i> |     |
| 89    |                     | <i>trans</i> -3-penten-2-one | <i>n</i> -Bu |                   |                                   | 52      | 64   | <i>S</i> |     |
| 90    |                     | <i>trans</i> -3-octen-2-one  | Me           |                   |                                   | 78      | 83   | <i>R</i> |     |
| 91    | 123                 | 2-cyclohexenone              |              |                   |                                   | 54      | 69   | <i>R</i> |     |
| 92    | 198                 |                              |              |                   | CuI                               |         | 20   | <i>R</i> | 94  |
| 93    |                     |                              |              |                   | CuBr                              |         | 30   | <i>R</i> |     |
| 94    |                     |                              | <i>n</i> -Bu |                   | CuI                               | 98      | 8    | <i>R</i> |     |
| 95    |                     |                              |              |                   | CuBr                              | 56      | 22   | <i>R</i> |     |
| 96    | 202                 |                              | Me           |                   | CuI                               | 100     | 30   | <i>R</i> |     |
| 97    |                     |                              |              |                   | CuBr                              | 95      | 46   | <i>R</i> |     |
| 98    |                     |                              |              | PhCH <sub>3</sub> | CuI                               | -       | 17   | <i>R</i> |     |
| 99    |                     |                              |              |                   | CuBr                              | -       | 40   | <i>R</i> |     |
| 100   |                     |                              |              | THF               |                                   | 29      | 0    | -        |     |
| 101   |                     |                              | <i>n</i> -Bu | ether             |                                   | 45      | 22   | <i>R</i> |     |
| 102   |                     |                              |              |                   | CuI                               | 100     | 10   | <i>R</i> |     |
| 103   |                     |                              |              | THF               | CuBr                              | 100     | 0    | -        |     |
| 104   | 205 ( <i>R,S</i> )  |                              |              | ether             | CuI                               |         | 37   | <i>R</i> |     |
| 105   |                     |                              |              |                   | CuBr                              |         | 70   | <i>R</i> |     |
| 106   |                     |                              |              |                   | CuBr/ <i>n</i> -Bu <sub>3</sub> P | 84      | 52   | <i>R</i> |     |
| 107   | 205 ( <i>R,R</i> )  |                              |              |                   | CuI                               |         | 25   | <i>R</i> |     |
| 108   |                     |                              |              |                   | CuBr                              |         | 66   | <i>R</i> |     |
| 109   |                     |                              |              |                   | CuBr/TMSCl                        | 91      | 0    | -        |     |
| 110   | 206                 |                              |              |                   | CuI                               | 82      | 26   | <i>S</i> |     |
| 111   |                     |                              |              |                   | CuBr                              | 60      | 28   | <i>S</i> |     |
| 112   | 168 ( <i>R</i> )    |                              | <i>n</i> -Bu | DMS               | CuI                               | 88      | 4    | <i>R</i> | 96  |
| 113   |                     |                              |              | ether             |                                   | 66      | 15   | <i>R</i> |     |
| 114   |                     | 2-cycloheptenone             |              |                   |                                   | 19      | 11   | <i>R</i> | 92  |
| 115   | 169                 | 2-cyclohexenone              |              |                   |                                   | 88      | 9    | <i>R</i> |     |
| 116   |                     |                              |              |                   |                                   | 62      | 13   | <i>R</i> |     |
| 117   | 171                 |                              |              | DMS               |                                   | 84      | 50   | <i>S</i> | 96  |
| 118   |                     |                              |              | ether/DMS         |                                   | 53      | 24   | <i>R</i> |     |
| 119   |                     |                              |              | ether             |                                   | 46      | 21   | <i>R</i> |     |
| 120   |                     |                              | Ph           | ether/DMS         |                                   | 44      | 10   | <i>R</i> |     |
| 121   |                     | 2-cycloheptenone             | <i>n</i> -Bu | ether             |                                   | 26      | 12   | <i>R</i> | 92  |
| 122   | 172                 | 2-cyclohexenone              |              | DMS               |                                   | 74      | 51   | <i>S</i> |     |
| 123   |                     |                              |              | DMS/ether         |                                   | 45      | 18   | <i>R</i> |     |
| 124   |                     |                              |              | ether             |                                   | 51      | 6    | <i>R</i> |     |
| 125   | 173                 |                              |              | DMS               |                                   | 64      | 29   | <i>R</i> | 96  |
| 126   |                     |                              |              | ether/DMS         |                                   | 28      | 8    | <i>S</i> |     |
| 127   | 174                 |                              |              | DMS               |                                   | 59      | 29   | <i>R</i> | 92  |
| 128   |                     |                              |              | ether/DMS         |                                   | 11      | 7    | <i>R</i> |     |
| 129   | 184                 |                              |              | DMS               |                                   | 43      | 43   | <i>R</i> | 96  |
| 130   |                     |                              |              | ether/DMS         |                                   | 25      | 3    | <i>S</i> |     |
| 131   |                     | 2-cycloheptenone             |              | ether             |                                   | 45      | 2    | <i>S</i> | 92  |
| 132   | 203                 | 2-cyclohexenone              |              |                   |                                   | 77      | 7    | <i>R</i> |     |
| 133   | 204                 |                              |              | DMS               |                                   | 7       | 8    | <i>S</i> |     |
| 134   | 207                 |                              |              |                   |                                   | 92      | 68   | <i>S</i> | 96  |
| 135   |                     |                              |              | ether/DMS         |                                   | 79      | 16   | <i>S</i> |     |
| 136   | 208                 | 2-cyclopentenone             | Me           | ether             |                                   | 40      | 32   | <i>R</i> | 97  |
| 137   |                     |                              | <i>n</i> -Bu |                   |                                   | 51      | 45   | <i>S</i> |     |
| 138   |                     | 2-cyclohexenone              | Me           |                   |                                   | 57      | 58   | <i>S</i> |     |
| 139   |                     |                              | <i>n</i> -Bu |                   |                                   | 92      | 83   | <i>S</i> |     |
| 140   |                     |                              |              | DMS               |                                   | 60      | 83   | <i>S</i> | 96  |
| 141   |                     |                              |              | THF               |                                   | 22      | 1    | <i>S</i> |     |
| 142   |                     |                              | Ph           | ether             |                                   | 30      | 97   | <i>S</i> |     |
| 143   |                     | 2-cycloheptenone             | Me           |                   |                                   | 60      | 97   | <i>S</i> | 97  |
| 144   |                     |                              | <i>n</i> -Bu |                   |                                   | 63      | 96   | ND       |     |
| 145   |                     | 2-cyclooctenone              | Me           |                   |                                   | 48      | 67   | ND       |     |
| 146   |                     |                              | <i>n</i> -Bu |                   |                                   | 50      | 86   | ND       |     |

Table 28. (Continued)

| entry | ligand <sup>b</sup> | substrate                 | R            | solvent   | CuX | % yield | % ee | R/S | ref |
|-------|---------------------|---------------------------|--------------|-----------|-----|---------|------|-----|-----|
| 147   | 209                 | 2-cyclohexenone           |              | ether     |     | 69      | 84   | S   | 92  |
| 148   |                     | 2-cycloheptenone          |              |           |     | 57      | 8    | S   |     |
| 149   |                     |                           | Me           |           |     | 4       | 95   | S   |     |
| 150   | 210                 | 2-cyclohexenone           | <i>n</i> -Bu |           |     | 71      | 55   | S   |     |
| 151   | 211                 | 2-cyclohexenone           | <i>n</i> -Bu |           |     | 52      | 19   | S   | 96  |
| 152   |                     |                           |              | DMS       |     | 49      | 10   | S   |     |
| 153   |                     | 2-cycloheptenone          |              | ether     |     | 76      | 4    | S   | 92  |
| 154   | 212                 | 2-cyclohexenone           | <i>n</i> -Bu | DMS       |     | 100     | 71   | S   | 96  |
| 155   |                     |                           |              | ether     |     | 75      | 55   | S   |     |
| 156   |                     |                           |              | THF       |     | 20      | 6    | S   |     |
| 157   |                     |                           | Ph           | ether/DMS |     | 51      | 71   | S   |     |
| 158   | 209                 |                           | <i>n</i> -Bu | DMS       |     | 39      | 4    | S   |     |
| 159   | 214                 |                           |              | ether     |     | 79      | 25   | S   |     |
| 160   |                     | 2-cycloheptenone          |              |           |     | 35      | 68   | S   | 92  |
| 161   | 215                 | 2-cyclohexenone           |              |           |     | 28      | 28   | S   | 96  |
| 162   | 216                 |                           |              |           |     | 63      | 19   | R   | 92  |
| 163   | 217                 |                           |              | DMS       |     | 2       | 1    | S   |     |
| 164   | 218                 |                           |              |           |     | 25      | 11   | R   |     |
| 165   | 219                 |                           |              |           |     | 58      | 32   | R   |     |
| 166   | 220                 |                           |              |           |     | 20      | 35   | R   |     |
| 167   | 198                 | 2-methyl-2-cyclopentenone | 2-propenyl   |           |     | 76      | 76   | R   | 95  |

<sup>a</sup> PhMgBr used instead of PhLi. <sup>b</sup> The ligands are as follows:



#### D. Lithium Diorganocuprates with Scalemic Noncovalently Bound Ligands

Several groups have synthesized and tested reagents made from various organometallic species and scalemic neutral organic ligands. One of the first examples of ECA was reported by Kretschmer in which Grignard

reagents plus catalytic CuCl were combined with sparteine (226) and reacted with several enones (Table 31).<sup>106</sup> The highest reported ee was 6%.

Several years later, Langer and Seebach reported using the chiral cosolvent, 2,3-dimethoxy-*N,N,N',N'*-tetramethyl-1,4-butanediamine (DDB, 227), to promote ECA to various substrates (Table 32).<sup>107</sup> Three types





Figure 14.

### Scheme 28. Enantioselective Synthesis of (+)-Confertin



of reagent were used: organocuprates, organozincates, and organolithiums. In general, the ee's were low although one reaction reached as high as 43% ee. The solvent, in principle, is available in substantial quantities. Given the expense of making or purchasing this solvent and the low ee's obtained in these reactions, it is currently not a useful approach for stereoselective conjugate addition.




Leyendecker examined a series of chiral ligands 228–237 derived from hydroxyproline in the reaction of lithium dimethyl cuprate with chalcone (Table 33).<sup>108</sup> In one case, ee's of 94% were obtained. They previously found that bidentate ligands give better results than unidentate ligands and reasoned that tridentate ligands would perform even better. They also discovered that N-carboalkoxylated and N-acylated ligands 230–232 and 234–237 gives better results than N-alkylated ligands 228, 229, and 231 and that dilution of the reaction mixtures does not change enantioselectivities. They postulated that simultaneous chelation of lithium and copper is important in order to attain high enantioselectivities (Figure 15). The proposal that the ligand chelates with copper runs counter to the suggestion of van Koten and Noltes that copper(I) in cuprates does not readily chelate with electron-rich ligands and therefore will not be an important aspect of enantioselective cuprate reagents.<sup>109</sup>

Recently, Alexakis, Mutti, and Normant reported using chiral phosphorus compounds derived from HMPA with *n*-BuCu to attain ECA with 2-cyclohexenone (Table 34).<sup>110</sup> The highest ee observed was 76% and depended in part on having 4 equiv of LiBr present

### Table 29. Catalytic Enantioselective Conjugate Addition of RMgX to 2-Cyclohexen-1-one

| entry | catalyst | R            | silyl reagent                                     | % yield | % ee            | R/S      |
|-------|----------|--------------|---|---------|-----------------|----------|
| 1     | 221      | <i>n</i> -Bu | -   | 96      | 20              | <i>S</i> |
| 2     | 222      |              |   | 89      | 15              | <i>S</i> |
| 3     |          |              | Me <sub>3</sub> SiCl                              | 95      | 51              | <i>S</i> |
| 4     |          |              |   | 98      | 60              | <i>S</i> |
| 5     |          |              |   | 63      | 0               |          |
| 6     |          |              | Ph <sub>2</sub> ( <i>t</i> -Bu)SiCl               | 26      | 70              | <i>S</i> |
| 7     |          |              |   | 53      | 74              | <i>S</i> |
| 8     | 221      |              |   | 57      | 74              | <i>S</i> |
| 9     |          |              |   | 97      | 78              | <i>S</i> |
| 10    |          |              |   | 51      | 27              | <i>S</i> |
| 11    | 222      |              | ( <i>i</i> -Pr) <sub>3</sub> SiOTf                | 98      | 44              | <i>S</i> |
| 12    | 221      |              | ( <i>t</i> -Bu) <sub>2</sub> Si(OTf) <sub>2</sub> | 67      | 40              | <i>S</i> |
| 13    |          | Me           | Me <sub>3</sub> SiCl                              | 54      | 30 <sup>a</sup> | <i>R</i> |
| 14    |          | Et           |   | 87      | 14              | <i>S</i> |
| 15    |          | vinyl        |   | 92      | 9               | <i>S</i> |
| 16    |          | Ph           |   | 96      | 0               |          |
| 17    |          | Me           | ( <i>t</i> -Bu) <sub>2</sub> MeSiOTf              | 95      | 10 <sup>a</sup> | <i>R</i> |
| 18    |          | Et           |   | 54      | 35              | <i>S</i> |
| 19    |          | Ph           | ( <i>t</i> -Bu) <sub>2</sub> MeSiOTf              | 57      | 0               |          |

<sup>a</sup> The enantiomeric form of the ligand was used.



- a. X = Me Ar\* = 225 R = 2-pyridyl 23% ee  
 b. X = Me Ar\* = 225 R = Me 4% ee  
 c. X = OMe Ar\* = 225 R = Me 1% ee

in the reaction mixture. Forming the organocopper reagent from Grignard reagents or using LiI gives poorer results than those reactions in which organolithium reagents and LiBr are used.


### E. Dialkylzinc Reagents and Scalemic Catalysts

Lucas et al. found that Ni(II) salts facilitate the conjugate addition of dialkylzinc to enones.<sup>111</sup> Several groups have taken this reaction and rendered it enantioselective. In their initial studies, Soai et al. reported that ECA to prochiral enones is possible using dialkylzinc reagents and Ni(acac)<sub>2</sub> in the presence of a chiral auxiliary.<sup>112,113</sup> The catalyst is formed by stirring 1 equiv of Ni(acac)<sub>2</sub> or NiBr<sub>2</sub> with *N,N*-dibutylnorephedrine (251) in toluene at 80 °C (Table 35, entries 1–6). The substrate is added, the reaction mixture is cooled to –30 °C, and Me<sub>2</sub>Zn or Et<sub>2</sub>Zn is added. The enantioselectivity in these reactions is partially a function of

Table 30. Enantioselective Conjugate Addition of Scalemic Azaenolates with 2-Cycloalkenones

n = 1 or 2

| entry | substrate        | metal-azaenolate                   | % yield | % ee | R/S | ref  |
|-------|------------------|------------------------------------|---------|------|-----|------|
| 1     | 2-cyclopentenone |                                    | 54      | 17   | R   | 104a |
| 2     |                  | R = CH <sub>2</sub> Ph             |         |      |     |      |
| 3     |                  | R = Pr <sup>i</sup>                | 75      | 27   | S   |      |
| 4     |                  | R = Bu <sup>t</sup> (R enantiomer) | 89      | 75   | R   |      |
| 5     |                  | R = CH <sub>2</sub> Ph             | 41      | 28   | R   |      |
| 6     |                  | R = Pr <sup>i</sup>                | 46      | 23   | R   |      |
| 7     |                  | R = Bu <sup>t</sup>                | 30      | 44   | S   |      |
| 8     |                  | R = Bu <sup>t</sup> (R enantiomer) | 31      | 44   | R   |      |
| 9     |                  |                                    | 73      | 92   | R   |      |
| 10    | 2-cyclohexenone  |                                    | 78      | 71   | S   |      |
| 11    |                  |                                    | 48      | 88   | S   |      |

Scheme 29. Enantioselective Synthesis of the Scalemic *trans*-Dihydrindandione System

the ratio of catalyst to substrate. Increasing the amount of catalyst gives better ee's.

Soai et al. later reported that the enantioselectivity of these reactions could be improved significantly by using a combination of Ni(II)-2,2'-dipyridyl chiral ligand in acetonitrile/toluene to form the catalyst.<sup>114</sup> ECA of dialkylzinc to aryl substituted enones affords  $\beta$ -substituted ketones in up to 90% ee (entries 15 and 16). In addition to the chiral ligand and Ni(II), both the achiral ligand and acetonitrile were essential in obtaining the product with high ee. Other achiral ligands were used as well, but not with the same degree of success.

Bolm and Ewald recently published the use of nickel-catalyzed ECA of organozinc reagents to  $\alpha,\beta$ -unsatur-

Table 31. Copper-Catalyzed Enantioselective Conjugate Addition of Grignard Reagents to Enones with Sparteine (226)

226

| entry          | substrate             | Grignard    | solvent | % yield | % ee |
|----------------|-----------------------|-------------|---------|---------|------|
| 1              | 2-cyclohexenone       | MeMgI/CuCl  | ether   | 17      | 6    |
| 2              |                       | PhMgBr/CuCl |         | 17      | <1   |
| 3 <sup>a</sup> | 1,2-diphenylpropenone | MeMgI/CuCl  | benzene | 45      | 3    |
| 4              |                       |             |         | 50      | 5    |
| 5              | 3-penten-2-one        | EtMgBr/CuCl | ether   | 10      | 5    |

<sup>a</sup> No copper(I) salt used.

ated ketones using the chiral 2,2'-dipyridyl ligand 254.<sup>115</sup> Optically active  $\beta$ -substituted ketones are obtained in high yields and with ee's as high as 74%. They have also observed asymmetric amplification with their system.<sup>116</sup> For example, when ligand 257 of 10% ee is used, product of 44% ee is obtained. Bolm suggests asymmetric amplification occurs as a result of the formation of dimeric nickel catalysts. If the nickel complexes with an unequal mixture of enantiomeric ligands, one can form *SS* (where *S* is the predominant enantiomer) and *SR* complexes. If the *SR* (meso) complex is relatively unreactive as a catalyst, one would expect the enantioselectivity of the reaction to be higher than the enantiomeric purity of the ligand. Although this reaction is catalytic in Ni, better ee's are obtained

Table 32. Enantioselective Conjugate Addition of Organometallic Reagents to Enones with DDB (227) as Cosolvent

227

| entry | substrate  | reagent  | solvent       | % yield | % ee       | R/S |
|-------|--|--|---------------|---------|------------|-----|
| 1     | 2-cyclohexenone                                      | Me <sub>2</sub> CuLi                                     | ether         | 54      | 14         | S   |
| 2     |  | Me <sub>3</sub> ZnLi                                     |               | 63      | [-0.74]    |     |
| 3     |  | ( <i>n</i> -Bu) <sub>2</sub> CuLi                        |               | 84      | 15         | S   |
| 4     |  |  |               | 65      | 7          | S   |
| 5     |  |  |               | 81      | 5          | S   |
| 6     |  |  |               | 45      | [-0.78]    |     |
| 7     |  | ( <i>n</i> -Bu) <sub>3</sub> ZnLi                        |               | 84      | 16         | S   |
| 8     |  |  |               | 81      | 24         | S   |
| 9     |  |  |               | 52      | [-1.04]    |     |
| 10    | 2-cyclopentenone                                     | (PhS) <sub>3</sub> CLi                                   |               | 80      | [-5.48]    |     |
| 11    |  | ( <i>n</i> -Bu) <sub>2</sub> CuLi                        |               | 64      | [-10.0]    |     |
| 12    |  | ( <i>n</i> -Bu) <sub>3</sub> ZnLi                        |               | 78      | [+6.93]    |     |
| 13    | crotonaldehyde                                       | [Me <sub>3</sub> Si](Me <sub>2</sub> S) <sub>2</sub> CLi |               | 38      | 5          |     |
| 14    |  | ( <i>n</i> -Bu) <sub>2</sub> CuLi                        |               | 63      | [-0.32]    |     |
| 15    |  | ( <i>n</i> -Bu) <sub>3</sub> ZnLi                        |               | 39      | [-0.32]    |     |
| 16    | cinnamaldehyde                                       | Me <sub>2</sub> CuLi                                     |               | 54      | [-0.10]    |     |
| 17    |  | ( <i>n</i> -Bu) <sub>2</sub> CuLi                        |               | 51      | [+0.61]    |     |
| 18    | 1,3-diphenyl-2-propenone                             | ( <i>n</i> -Bu) <sub>2</sub> CuLi                        |               | 75      | [-0.75]    |     |
| 19    | 2-(2-cyclohexenylidene)-1,3-dithiane<br>nitropropene | <i>n</i> -BuLi   |               | 78      | [-9.5]     |     |
| 20    |  |  | pentane       | 49      | 28         | R   |
| 21    |  | ( <i>n</i> -Bu) <sub>2</sub> CuLi                        |               | 49      | 27         | R   |
| 22    |  |  | pentane/ether | 54      | 15         | R   |
| 23    |  | ( <i>n</i> -Bu) <sub>3</sub> ZnLi                        |               | 59      | 27         | R   |
| 24    |  |  |               | 54      | 15         | R   |
| 25    |  |  |               | 72      | 43         |     |
| 26    | <i>β</i> -nitrostyrene                               |  |               | 62      | [+0.054]   |     |
| 27    |  |  |               | 80      | [-4.25]    |     |
| 28    |  | <i>n</i> -BuLi   |               | 60      | [+1.22]    |     |
| 29    |  |  |               | 55      | [+0.43]    |     |
| 30    | nitropropene   |  |               | 48      | [-0.39]    |     |
| 31    |  |  |               | 70      | 6/[+0.12]  |     |
| 32    |  |  |               | 75      | [+0.10]    |     |
| 33    |  |  |               | 57      | 12/[+0.64] |     |
| 34    | <i>β</i> -nitrostyrene                               |  |               | 68      | 10/[+1.25] |     |




Figure 15.


when more reagent is used (compare entries 27 and 28 vs 32–34).

Soai et al. have also described ECA of diethylzinc to enones using chiral  $\beta$ -amino alcohol, 1-phenyl-2-(1-piperidiny)propan-1-ol **255** and **256** in catalytic and sto-

ichiometric amounts to facilitate the reaction. No additional transition metal catalyst is added.<sup>117</sup> When enones **246** and **248–250** are reacted with Et<sub>2</sub>Zn using 0.25 equiv of the 1*S*,2*R* isomer, **255**, the corresponding ketone products are obtained with 60–80% ee (entries 37, 40, and 42). When a stoichiometric amount of **255** is employed, ee's of the product increase to 81–94% (entries 38, 39, 41, 43, and 44). Reaction times appear to be considerably longer than those employing nickel catalysts.


#### F. Grignard Reagents Catalyzed by Scalemic Arenethiolatocopper(I) Complexes

van Koten et al. recently described the catalytic conjugate addition of MeMgI to 4-phenyl-3-buten-2-

**Table 33. Enantioselective Conjugate Addition of  $\text{LiCuMe}_2$  to Chalcone Using Noncovalently Bound Hydroxyproline-Derived Ligands**



| entry | ligand                              | % yield | % ee |
|-------|-------------------------------------|---------|------|
| 1     | 228, R = neopentyl                  | 98      | 2    |
| 2     | 229, R = methyl                     | 97      | 7    |
| 3     | 230, R = <i>t</i> -BOC              | 95      | 33   |
| 4     | 231, R = acetyl                     | 71      | 33   |
| 5     | 232, R = trimethylacetyl            | 93      | 68   |
| 6     | 233, R = <i>t</i> -Bu               | 95      | 75   |
| 7     | 234, R = 1-phenylcyclohexylcarbonyl | 95      | 50   |
| 8     | 235, R = isobutanoyl                | >90     | 58   |
| 9     | 236, R = benzoyl                    | >90     | 85   |
| 10    | 237, R = 1-naphthoyl                | >90     | 94   |

one in up to 57% ee using the chiral arenethiolato-copper(I) complex shown below (eq 20).<sup>118</sup> This complex is similar to achiral complexes that have been developed and structurally characterized.<sup>119</sup> The reaction is performed by dissolving the thiolato complex and 4-phenyl-3-buten-2-one in ether at 0 °C and adding MeMgI slowly. When excess MeMgI is present in the reaction mixture, the enantioselectivity of the reaction is low (ca. 3%). The mixed cuprate,  $\text{LiCu}(\text{SAr})(\text{Me})$  gives predominantly 1,4-addition but is not enantioselective.




### G. Grignard Reagents with Scalemic Zinc Catalysts

Isobe et al. found that lithium trialkylzincates react with enones to give conjugate addition.<sup>120</sup> Others discovered that alkoxides could be substituted for some of the alkyl groups as nontransferable ligands.<sup>121</sup> Jansen and Feringa subsequently found that  $N,N,N',N'$ -tetramethylethylenediamine complexes of  $\text{ZnCl}_2$  catalyze the conjugate addition of Grignard reagents to enones.<sup>122</sup> Using this reaction, Jansen and Feringa screened a number of chiral ligands to see if they could render this reaction enantioselective (Table 36).<sup>123</sup> They looked at the conjugate addition of various alkyl moieties to 2-cyclohexenone. As part of their study, they also looked at the influence of solvent, counterions, rate of addition, and temperature. The advantage of this system is that it is catalytic and uses inexpensive and readily prepared Grignard reagents. In general, the reactions proceed with high chemical yields and selectivity for 1,4 vs 1,2 addition. The enantioselectivities, however, are poor, reaching only as high as 33% in one case. They found the highest enantioselectivities are attained by preparing the catalyst in situ from the lithium salt of the chiral diamino alcohol ligand and performing the reaction in THF. A mechanism was suggested for this reaction in which 2-cyclohex-


**Table 34. Enantioselective Conjugate Addition to 2-Cyclohexenone with Organocopper Reagents and Scalemic Noncovalently Bound Phosphorus Ligands**


| entry | <i>n</i> -BuM               | ligand <sup>a</sup> | copper source and added salts  | ligand equiv | solvent           | % yield | % ee |
|-------|-----------------------------|---------------------|--------------------------------|--------------|-------------------|---------|------|
| 1     | BuLi/hexane                 | 238                 | CuI                            | 1            | THF               | 30      | 22   |
| 2     |                             |                     |                                | 2            |                   | 35      | 38   |
| 3     |                             |                     |                                | 3            |                   | 43      | 19   |
| 4     |                             |                     |                                | 2            | Et <sub>2</sub> O | 43      | 22   |
| 5     |                             |                     | CuI + TMSCl                    |              | THF               | 15      | 0    |
| 6     |                             |                     | CuI + 4LiBr                    |              |                   | 56      | 65   |
| 7     |                             |                     | CuI + 4LiI                     |              |                   | 45      | 44   |
| 8     |                             |                     | CuBr-Me <sub>2</sub> S + 4LiBr |              |                   | 45      | 40   |
| 9     | BuLi-LiBr/Et <sub>2</sub> O |                     | CuI + 3LiBr                    |              |                   | 62      | 62   |
| 10    | BuMgBr/Et <sub>2</sub> O    |                     | CuI + 4LiBr                    |              |                   | 28      | 19   |
| 11    | 0.5 equiv BuLi/hexane       |                     |                                |              |                   | 27      | 75   |
| 12    | 2 equiv BuLi/hexane         |                     |                                |              |                   | >90     | 0-75 |
| 13    | BuLi/hexane                 | 239                 |                                |              |                   | 61      | 76   |
| 14    |                             | 240                 |                                |              |                   | 10      | 62   |
| 15    |                             | 241                 |                                |              |                   | 12      | 14   |
| 16    |                             | 242                 |                                |              |                   | 55      | rac  |
| 17    |                             | 243                 |                                |              |                   | 62      | 23   |


<sup>a</sup> The ligands are as follows:



238 R = Me, R<sub>1</sub> = NMe<sub>2</sub>  
 239 R = Me, R<sub>1</sub> = Ph  
 240 R = *i*-Pr, R<sub>1</sub> = NMe<sub>2</sub>  
 241 R = Me, R<sub>1</sub> = morpholinyl




242



243




Table 35. Catalyzed Enantioselective Conjugate Addition of Dialkylzinc to Enones



| entry | NiX <sub>2</sub>      | ligand <sup>a</sup>       | substrate | R    | Ni:L*:S   | % yield | % ee | R/S | ref |
|-------|-----------------------|---------------------------|-----------|------|-----------|---------|------|-----|-----|
| 1     | Ni(acac) <sub>2</sub> | 251                       | 244       | Me   | 1:1.2:1.7 | 72      | 40   | R   | 112 |
| 2     |                       |                           |           | Et   | 1:1.2:2.0 | 75      | 45   | R   |     |
| 3     |                       |                           |           |      | 1:1.2:1.7 | 94      | 20   | R   |     |
| 4     |                       | 252                       |           |      | 1:1.2:1.7 | 89      | 22   | S   |     |
| 5     |                       | 251                       | 245       |      | 1:1.2:1.7 | 63      | 12   | R   |     |
| 6     |                       |                           | 246       |      | 1:1.2:2.0 | 78      | 44   | R   |     |
| 7     | NiBr <sub>2</sub>     |                           | 244       |      | 1:1.2:4.0 | 32      | 48   | R   | 113 |
| 8     |                       |                           |           |      | 1:1.2:3.3 | NR      | 36   | R   |     |
| 9     |                       |                           |           |      | 1:1.2:2.5 | NR      | 32   | R   |     |
| 10    | NiCl <sub>2</sub>     |                           |           |      | 1:1.2:4   | NR      | 30   | R   |     |
| 11    | NiI <sub>2</sub>      |                           |           |      |           | NR      | 3    | R   |     |
| 12    | NiBr <sub>2</sub>     |                           |           | n-Bu |           | 16      | 43   | ND  |     |
| 13    |                       |                           | 245       | Et   |           | 32      | 18   | S   |     |
| 14    |                       |                           | 246       |      |           | 40      | 14   | S   |     |
| 15    | Ni(acac) <sub>2</sub> | 251/2,2'-bipyridyl        | 244       |      | 1:2.4:14  | 47      | 90   | R   | 114 |
| 16    |                       | 253/2,2'-bipyridyl        |           |      | 1:2.4:17  | 63      | 82   | R   |     |
| 17    |                       | 251/piperazine            |           |      |           | 44      | 87   | R   |     |
| 18    |                       | 251/1,10-phenanthroline   |           |      |           | 72      | 81   | R   |     |
| 19    |                       | 251/2,2'-bipyridyl        |           | n-Bu | 1:2.4:14  | 47      | 74   | R   |     |
| 20    |                       | 251/2,2'-bipyridyl        | 247       | Et   |           | 58      | 80   | R   |     |
| 21    |                       | 251/2,2'-bipyridyl ketone | 244       |      | 1:2.4:17  | 87      | 71   | R   |     |
| 22    |                       | 251/2,2'-biquinoline      |           |      |           | 92      | 70   | R   |     |
| 23    |                       | 251/1,2-DPPE              |           |      |           | 89      | 71   | R   |     |
| 24    |                       | 251/morpholine            |           |      |           | 84      | 71   | R   |     |
| 25    |                       | 251/quinuclidine          |           |      |           | 85      | 72   | R   |     |
| 26    |                       | 251/pyridine              |           |      |           | 84      | 71   | R   |     |
| 27    |                       | 254                       |           |      | 1:30:100  | 55      | 72   | R   | 115 |
| 28    |                       |                           |           |      | 1:20:100  | 75      | 72   | R   |     |
| 29    |                       |                           |           |      | 1:10:100  | 82      | 54   | R   |     |
| 30    |                       |                           |           |      | 1:5:100   | 74      | 20   | R   |     |
| 31    |                       |                           |           |      | 1:5:50    | 66      | 48   | R   |     |
| 32    |                       |                           |           |      | 1:3:50    | 73      | 18   | R   |     |
| 33    |                       |                           |           |      | 1:3:20    | 58      | 58   | R   |     |
| 34    |                       |                           |           |      | 1:1:20    | 69      | 18   | R   |     |
| 35    |                       |                           | 247       |      | 1:10:20   | 68      | 74   | ND  |     |
| 36    |                       |                           | 245       |      | 1:5:20    | 76      | 2    | R   |     |
| 37    |                       | 255                       | 248       |      | 0:1:4     | 81      | 80   | (+) | 117 |
| 38    |                       |                           |           |      | 0:1:1     | 96      | 94   | (+) |     |
| 39    |                       | 256                       |           |      |           | 95      | 93   | (-) |     |
| 40    |                       | 255                       | 249       |      | 0:1:4     | 82      | 72   | R   |     |
| 41    |                       |                           |           |      | 0:1:1     | 84      | 81   | R   |     |
| 42    |                       |                           | 250       |      | 0:1:4     | 88      | 60   | ND  |     |
| 43    |                       |                           |           |      | 0:1:1     | 84      | 82   | ND  |     |
| 44    |                       |                           | 246       |      |           | 34      | 82   | R   |     |
| 45    |                       | 257                       | 244       |      | 0:30:100  | 62      | 86   | R   | 116 |
| 46    |                       | 258                       | 244       |      | 1:20:100  | NG      | 86   | R   |     |

<sup>a</sup> The ligands are as follows:




enone is tethered to the chiral tetracoordinated alkylzinc complex through the carbonyl oxygen (Figure 16). The Grignard reagent also becomes tethered to the zinc complex through the alkoxide oxygen. The enone and Grignard, having been brought into close proximity, react with transfer of the alkyl group to the  $\beta$ -position of the enone. The mechanism does not attempt to account for the stereochemical outcome of the reaction.

#### IV. Enantioselective Conjugate Addition of Organolithium Reagents to Prochiral $\alpha,\beta$ -Unsaturated Aldimines

Tomioka, Shindo, and Koga have developed a protocol for ECA of organolithium compounds to  $\alpha,\beta$ -unsaturated aldimines using enantiomerically pure C<sub>2</sub> symmetric diethers and a diamine to direct the ster-

**Table 36. Enantioselective Conjugate Addition of Grignard Reagents to 2-Cyclohexenone Using Chiral Zinc Complexes**

| entry | catalyst <sup>a</sup> | R            | X  | note    | % yield | % ee |
|-------|-----------------------|--------------|----|---------|---------|------|
| 1     | 259                   | <i>i</i> -Pr | Br |         | 91      | 18   |
| 2     | 260                   |              |    |         | 90      | 16   |
| 3     |                       |              |    |         | 90      | 26   |
| 4     |                       |              |    |         | 95      | 26   |
| 5     | 259                   | Et           | Br |         | 68      | 4    |
| 6     |                       | <i>n</i> -Bu |    |         | 74      | 5    |
| 7     |                       | <i>i</i> -Pr | Cl |         | 97      | 22   |
| 8     |                       |              | I  |         | 65      | 9    |
| 9     |                       | <i>n</i> -Bu | Cl |         | 96      | 9    |
| 10    |                       |              | I  |         | 69      | 0    |
| 11    | 260                   | <i>i</i> -Pr | Cl |         | 97      | 17   |
| 12    |                       |              | Br |         | 92      | 26   |
| 13    |                       |              | I  |         | 49      | 3    |
| 14    |                       |              | Cl | 0 °C    | 81      | 7    |
| 15    | 262                   |              |    | 0 °C    | 75      | 7    |
| 16    |                       |              |    | -90 °C  | 97      | 17   |
| 17    | 263                   |              |    | LiOt-Bu | 95      | 21   |
| 18    |                       |              |    | NaOt-Bu | 89      | 11   |
| 19    |                       |              |    | KOt-Bu  | 93      | 17   |
| 20    | 261                   | <i>i</i> -Pr | Br |         | 87      | 17   |
| 21    | 264                   |              |    |         | 83      | 14   |
| 22    | 265                   |              | Cl |         | 93      | 17   |
| 23    | 266                   |              |    |         | 91      | 21   |
| 24    | 267                   |              |    |         | 85      | 17   |
| 25    | 159                   |              |    |         | 95      | 15   |
| 26    | 160                   |              |    |         | 92      | 16   |
| 27    | 128                   |              |    |         | 96      | 13   |
| 28    | 129                   |              |    |         | 87      | 5    |
| 29    | 268                   |              |    |         | 89      | 21   |
| 30    | 269                   |              |    |         | 97      | 3    |
| 31    | 270                   |              |    |         | 95      | 11   |
| 32    | 152                   |              |    |         | 91      | 21   |
| 33    | 271                   |              |    |         | 88      | 4    |
| 34    | 272                   |              |    |         | 87      | 4    |
| 35    | 273                   |              |    |         | 95      | 6    |
| 36    | 274                   |              |    |         | 96      | 8    |
| 37    | 275                   |              |    |         | 94      | 16   |
| 38    | 276                   |              |    |         | 99      | 17   |
| 39    | 277                   |              |    |         | 87      | 6    |
| 40    | 278                   |              |    |         | 89      | 10   |

<sup>a</sup> Catalysts are as follows:

eochemical course of addition (Table 37).<sup>124</sup> The reaction does not occur readily in the absence of the chiral diethers or diamine. As shown, the reaction works well with both cyclic and acyclic aldimines.

The reaction is believed to occur by forming a lithium complex which includes the bidentate chiral ligand, the alkyl group and the aldimine via complexation with the nitrogen (Figure 17). Transfer of the R group to






Figure 16. Mechanism of zinc-catalyzed conjugate addition of Grignard reagents.

Table 37. Enantioselective Conjugate Addition of Organolithium Reagents to  $\alpha,\beta$ -Unsaturated Aldimines in the Presence of Chiral  $C_2$  Symmetric Diethers



| entry | imine <sup>a</sup> | R            | chiral diether <sup>b</sup> | % yield | % ee | config                 |
|-------|--------------------|--------------|-----------------------------|---------|------|------------------------|
| 1     | 279                | <i>n</i> -Bu | 285                         | 80      | 91   | 1 <i>R</i> ,2 <i>S</i> |
| 2     |                    |              | 286                         | 92      | 53   |                        |
| 3     |                    |              | 287                         | 46      | 6    |                        |
| 4     |                    |              | 288                         | 26      | 11   | 1 <i>S</i> ,2 <i>R</i> |
| 5     |                    | Ph           | 285                         | 82      | 94   | 1 <i>R</i> ,2 <i>S</i> |
| 6     |                    |              | 286 ( <i>S,S</i> )          | 68      | 90   | 1 <i>S</i> ,2 <i>R</i> |
| 7     | 280                |              | 285                         | 61      | 96   | 1 <i>S</i> ,2 <i>S</i> |
| 8     |                    |              | 286 ( <i>S,S</i> )          | 69      | 80   | 1 <i>R</i> ,2 <i>R</i> |
| 9     | 281                |              | 285                         | 59      | 98   | 1 <i>S</i> ,2 <i>S</i> |
| 10    |                    |              | 286 ( <i>S,S</i> )          | 76      | 90   | 1 <i>R</i> ,2 <i>R</i> |
| 11    | 282                |              | 285                         | 58      | >99  | <i>S</i>               |
| 12    |                    |              | 286 ( <i>S,S</i> )          | 45      | 93   | <i>R</i>               |
| 13    | 283                | <i>n</i> -Bu | 285                         | 40      | 82   | <i>R</i>               |
| 14    | 284                | Ph           | 285                         | 48      | >99  | <i>S</i>               |
| 15    |                    |              | 286 ( <i>S,S</i> )          | 42      | 94   | <i>R</i>               |

<sup>a</sup>Imines are as follows:



<sup>b</sup>Chiral diethers are as follows:




Figure 17.

the bottom face of the olefin yields, after hydrolysis, the product.

#### IV. Summary

Over the last 25 years, many approaches to the problem of asymmetric conjugate addition to  $\alpha,\beta$ -unsaturated substrates have been investigated. A variety of very successful methods have been developed for diastereoselective conjugate addition to acyclic and cyclic scalemic  $\alpha,\beta$ -unsaturated substrates. In a few

instances, high enantioselectivities have been achieved in the conjugate addition of scalemic reagents with prochiral cyclic and acyclic  $\alpha,\beta$ -unsaturated ketones. Good asymmetric induction has also been demonstrated with acyclic aldimines. The ideal reagent for asymmetric conjugate addition, of course, is a scalemic catalyst which promotes enantioselective conjugate addition of readily available organometallic reagents such as Grignard and organolithium reagents to a wide variety of cyclic and acyclic  $\alpha,\beta$ -unsaturated substrates in high chemical yield and high enantioselectivity. The reagent capable of doing this has not yet been developed and remains an important challenge in synthetic organic reagent development.

#### VI. References

- Perlmutter, P. *Conjugate Addition Reactions in Organic Synthesis*; Tetrahedron Organic Chemistry Series, No. 9; Pergamon: Oxford, 1992.
- Lee, V. J. In *Comprehensive Organic Synthesis*; Trost, B. M., Fleming, I., Eds.; Pergamon: Oxford, 1991; Vol. 4, Chapter 1.2.
- (a) Kozlowski, J. A. In *Comprehensive Organic Synthesis*; Trost, B. M., Fleming, I., Eds.; Pergamon: Oxford, 1991; Vol. 4, Chapter 1.4. (b) Posner, G. H. *Org. React.* 1972, 19, 1. (c) Posner, G. H. *An Introduction to Synthesis Using Organocuprate Reagents*; Wiley: New York, 1980. (d) Lipschutz, B. H.; Wilhelm, R. S.; Kozlowski, J. A. *Tetrahedron* 1984, 40, 5005. (e) Lipschutz, B. H. *Synthesis* 1987, 325. (f) Jukes, A. E. *Adv. Organomet. Chem.* 1974, 12, 215.
- For previous reviews of stereoselective conjugate additions see: (a) Schmalz, H.-G. In *Comprehensive Organic Synthesis*; Trost, B. M., Fleming, I., Eds.; Pergamon: Oxford, 1991; Vol. 4, Chapter 1.5. (b) Tomioka, K.; Koga, K. In *Asymmetric Synthesis*; Morrison, J. D., Ed.; Academic: New York, 1983; Vol. 2, p 201.
- The term scalemic refers to unequal mixtures of enantiomers; Heathcock, C. H.; Finkelstein, B. L.; Jarvi, E. T.; Radel, P. A.; Hadley, C. R. *J. Org. Chem.* 1988, 53, 1922.
- Kharasch, M. S.; Tawney, P. O. *J. Am. Chem. Soc.* 1941, 63, 2308.
- Bitsch, V.; Jacobsen, S.; Andersen, I. G. K.; Munch-Petersen, J. *Acta Chem. Scand.* 1963, 17, 1433 and references cited therein.
- Kawana, M.; Emoto, S. *Bull. Chem. Soc. Jpn.* 1966, 39, 910.
- Inouye, Y.; Walborsky, H. M. *J. Org. Chem.* 1962, 27, 2706.
- Gustafsson, B.; Hansson, A.-T.; Ullenius, C. *Acta Chem. Scand., Ser. B* 1980, 34, 113.
- Yamamoto, Y.; Maruyama, K. *J. Am. Chem. Soc.* 1978, 100, 3240.
- Oppolzer, W.; Löher, H. *J. Helv. Chim. Acta* 1981, 64, 2808.
- Oppolzer, W.; Moretti, R.; Godel, T.; Meunier, A.; Löher, H. *Tetrahedron Lett.* 1983, 24, 4971.
- For a review of reactions involving camphor-derived chiral auxiliaries, see: Oppolzer, W. *Tetrahedron* 1987, 43, 1969.
- Oppolzer, W.; Stevenson, T. *Tetrahedron Lett.* 1986, 27, 1139.
- Oppolzer, W.; Moretti, R. *Tetrahedron* 1987, 43, 1969.
- Oppolzer, W.; Godel, T. *Tetrahedron* 1987, 43, 1969.
- Oppolzer, W.; Dudfield, P.; Stevenson, T.; Godel, T. *Helv. Chim. Acta* 1985, 68, 212.
- Oppolzer, W.; Moretti, R.; Bernardinelli, G. *Tetrahedron Lett.* 1986, 27, 4713.
- Somfai, P.; Tanner, D.; Olsson, T. *Tetrahedron* 1985, 41, 5973.
- Bergdahl, M.; Nilsson, M.; Olsson, T. *J. Organomet. Chem.* 1990, 391, C19.
- Helmchen, G.; Wegner, G. *Tetrahedron Lett.* 1985, 26, 6047.
- Helmchen, G.; Wegner, G. *Tetrahedron Lett.* 1985, 26, 6051.
- (a) Fang, C.; Suemune, H.; Sakai, K. *Tetrahedron Lett.* 1990, 31, 4751. (b) Fang, C.; Ogawa, T.; Suemune, H.; Sakai, K. *Tetrahedron: Asymmetry* 1991, 2, 389.
- Fleming, I.; Kindon, N. D. *J. Chem. Soc., Chem. Commun.* 1987, 1177.
- Fuji, K.; Tanaka, K.; Mizuchi, M.; Hosoi, S. *Tetrahedron Lett.* 1991, 32, 7277.
- Alexakis, A.; Sedrani, R.; Mangeney, P.; Normant, J. F. *Tetrahedron Lett.* 1988, 29, 4411.
- Asami, M.; Mukaiyama, T. *Chem. Lett.* 1979, 569.
- (a) Scolastico, C. *Pure Appl. Chem.* 1988, 60, 1689. (b) Bernardi, A.; Cardani, S.; Pilati, T.; Poli, G.; Scolastico, C.; Villa, R. *J. Org. Chem.* 1988, 53, 1600. (c) Bernardi, A.; Cardani, S.; Poli, G.; Scolastico, C. *J. Org. Chem.* 1986, 51, 5043.
- Mukaiyama, T.; Iwasawa, N. *Chem. Lett.* 1981, 913.
- Kogure, T.; Eliel, E. L. *J. Org. Chem.* 1984, 49, 576.
- (a) Mukaiyama, T.; Takeda, T.; Osaki, M. *Chem. Lett.* 1977, 1165. (b) Mukaiyama, T.; Takeda, T.; Fujimoto, K. *Bull. Chem. Soc. Jpn.* 1978, 51, 3368. (c) Mukaiyama, T.; Fujimoto, K.; Takeda, T. *Chem. Lett.* 1979, 1207. (d) Mukaiyama, T.; Fujimoto, K.; Hirose, T.; Takeda, T. *Chem. Lett.* 1980, 635.
- Takeda, T.; Mukaiyama, T. *Chem. Lett.* 1980, 163.
- Soai, K.; Machida, H.; Yokota, N. *J. Chem. Soc. Perkin Trans. 1* 1987, 1909.

- (35) Soai, K.; Machida, H.; Ookawa, A. *J. Chem. Soc., Chem. Commun.* 1985, 469.
- (36) Soai, K.; Ookawa, A. *J. Chem. Soc. Perkin Trans. 1* 1986, 759.
- (37) Tomioka, K.; Suenaga, T.; Koga, K. *Tetrahedron Lett.* 1986, 27, 369.
- (38) Oppolzer, W.; Mills, R. J.; Pachinger, W.; Stevenson, T. *Helv. Chim. Acta* 1986, 69, 1542.
- (39) Oppolzer, W.; Poli, G.; Kingma, A. J.; Starkemann, C.; Bernardinelli, G. *Helv. Chim. Acta* 1987, 70, 2201.
- (40) Oppolzer, W.; Kingma, A. J. *Helv. Chim. Acta* 1989, 72, 1337.
- (41) Oppolzer, W.; Kingma, A. J.; Poli, G. *Tetrahedron* 1989, 45, 479.
- (42) Oppolzer, W.; Schneider, P. *Helv. Chim. Acta* 1986, 69, 1817.
- (43) (a) Posner, G. H. *Acc. Chem. Res.* 1987, 20, 72. (b) Posner, G. H. In *Asymmetric Synthesis*; Morrison, J. D., Ed.; Academic: New York, 1983; Vol. 2, p 239.
- (44) Posner, G. H.; Frye, L. L.; Hulce, M. *Tetrahedron* 1984, 40, 1401.
- (45) Posner, G. H.; Frye, L. L. *Isr. J. Chem.* 1984, 24, 88.
- (46) Saengchantara, S. T.; Wallace, T. W. *Tetrahedron* 1990, 46, 6553.
- (47) Schultz, A. G.; Harrington, R. E. *J. Am. Chem. Soc.* 1991, 113, 4926.
- (48) Smith, A. B.; Dunlap, N. K.; Sulikowski, G. A. *Tetrahedron Lett.* 1987, 28, 439.
- (49) Jung, M. E.; Lew, W. *Tetrahedron Lett.* 1990, 31, 623.
- (50) Vemura, M.; Oda, H.; Minami, T.; Hayashi, Y. *Tetrahedron Lett.* 1991, 32, 4565.
- (51) Alexakis, A.; Mangeney, P.; Ghribi, A.; Marek, I.; Sedrani, R.; Guir, C.; Normant, J. F. *Pure Appl. Chem.* 1988, 60, 49.
- (52) (a) Fujiwara, J.; Fukutani, Y.; Hasegawa, M.; Maruoka, K.; Yamamoto, H. *J. Am. Chem. Soc.* 1984, 106, 5004. (b) Fukutani, Y.; Maruoka, K.; Yamamoto, H. *Tetrahedron Lett.* 1984, 25, 5911.
- (53) (a) Berlan, J.; Besace, Y.; Pourcelot, G.; Cresson, P. *Tetrahedron* 1986, 42, 4757. (b) Besace, Y.; Berlan, J.; Pourcelot, G.; Huche, M. *J. Organomet. Chem.* 1983, 247, C11. (c) Mangeney, P.; Alexakis, A.; Normant, J. F. *Tetrahedron Lett.* 1983, 24, 373. (d) Huche, M.; Aubouet, J.; Pourcelot, G.; Berlan, J. *Tetrahedron Lett.* 1983, 24, 585.
- (54) (a) Berlan, J.; Besace, Y. *Tetrahedron* 1986, 42, 4767. (b) Berlan, J.; Besace, Y.; Prat, D.; Pourcelot, G. *J. Organomet. Chem.* 1984, 264, 399. (c) Berlan, J.; Besace, Y.; Pourcelot, G.; Cresson, P. *J. Organomet. Chem.* 1983, 256, 181.
- (55) Mangeney, P.; Alexakis, A.; Normant, J. F. *Tetrahedron* 1984, 40, 1803.
- (56) (a) Meyers, A. I.; Whitten, C. E. *J. Am. Chem. Soc.* 1975, 97, 6266. (b) Meyers, A. I.; Smith, R. K.; Whitten, C. E. *J. Org. Chem.* 1979, 44, 2250.
- (57) Meyers, A. I.; Whitten, C. E. *Heterocycles* 1976, 4, 1687.
- (58) Meyers, A. I.; Shipman, M. J. *J. Org. Chem.* 1991, 56, 7098.
- (59) Meyers, A. I.; Smith, R. K. *Tetrahedron Lett.* 1979, 2749.
- (60) Ziegler, F. E.; Gilligan, P. J. *J. Org. Chem.* 1981, 46, 3874.
- (61) Meyers, A. I.; Lutomski, K. A. *J. Am. Chem. Soc.* 1982, 104, 879.
- (62) Wilson, J. N.; Cram, D. J. *J. Am. Chem. Soc.* 1982, 104, 881.
- (63) Meyers, A. I.; Himmelsbach, R. J. *J. Am. Chem. Soc.* 1985, 107, 682.
- (64) Meyers, A. I.; Flisak, J. R.; Aitken, R. A. *J. Am. Chem. Soc.* 1987, 109, 5446.
- (65) Warshawsky, A. M.; Meyers, A. I. *J. Am. Chem. Soc.* 1990, 112, 8090.
- (66) Meyers, A. I.; Meier, A.; Rawson, D. J. *Tetrahedron Lett.* 1992, 33, 853.
- (67) (a) Meyers, A. I.; Natale, N. R.; Wettlaufer, D. G.; Rafii, S.; Clardy, J. *Tetrahedron Lett.* 1981, 5123. (b) Meyers, A. I.; Natale, N. R. *Heterocycles* 1982, 18, 13.
- (68) Gosmini, R.; Mangeney, P.; Alexakis, A.; Commerçon, M.; Normant, J. F. *Synlett* 1991, 111.
- (69) Mangeney, P.; Gosmini, R.; Alexakis, A. *Tetrahedron Lett.* 1991, 32, 3981.
- (70) (a) Meyers, A. I.; Roth, G. P.; Hoyer, D.; Barner, B. A.; Laucher, D. *J. Am. Chem. Soc.* 1988, 110, 4611. (b) Barner, B. A.; Meyers, A. I. *J. Am. Chem. Soc.* 1984, 106, 1865. (c) Meyers, A. I.; Hoyer, D. *Tetrahedron Lett.* 1984, 25, 66. (d) Meyers, A. I.; Barner, B. A. *J. Org. Chem.* 1986, 51, 120.
- (71) Rawson, D. J.; Meyers, A. I. *J. Org. Chem.* 1991, 56, 2292.
- (72) Andrews, R. C.; Teague, S. J.; Meyers, A. I. *J. Am. Chem. Soc.* 1988, 110, 7854.
- (73) Meyers, A. I.; Higashiyama, K. *J. Org. Chem.* 1987, 52, 4592.
- (74) Roth, G. P.; Rithner, C. D.; Meyers, A. I. *Tetrahedron* 1989, 45, 6949.
- (75) Robichaud, A. J.; Meyers, A. I. *J. Org. Chem.* 1991, 56, 2607.
- (76) Meyers, A. I.; Licini, G. *Tetrahedron Lett.* 1989, 30, 4049.
- (77) (a) Hashimoto, S.; Yamada, S.; Koga, K. *J. Am. Chem. Soc.* 1976, 98, 7450. (b) Hashimoto, S.; Yamada, S.; Koga, K. *Chem. Pharm. Bull.* 1979, 27, 771.
- (78) Hashimoto, S.; Kogen, H.; Tomioka, K.; Koga, K. *Tetrahedron Lett.* 1979, 3009.
- (79) Tomioka, K.; Masumi, F.; Yamashita, T.; Koga, K. *Tetrahedron Lett.* 1984, 25, 333.
- (80) (a) Kogen, H.; Tomioka, K.; Hashimoto, S.; Koga, K. *Tetrahedron Lett.* 1980, 21, 4005. (b) Kogen, H.; Tomioka, K.; Hashimoto, S.; Koga, K. *Tetrahedron* 1981, 37, 3951.
- (81) Meyers, A. I.; Brown, J. D.; Laucher, D. *Tetrahedron Lett.* 1987, 28, 5283.
- (82) Zweig, J. S.; Luche, J. L.; Barreiro, E.; Crabbé, P. *Tetrahedron Lett.* 1975, 2355.
- (83) Ghosland, F.; Luche, J. L.; Crabbé, P. *Bull. Soc. Chim. Belg.* 1978, 87, 369.
- (84) Huche, M.; Berlan, J.; Pourcelot, G.; Cresson, P. *Tetrahedron Lett.* 1981, 22, 1329.
- (85) Gustafsson, B.; Hallnemo, G.; Ullenius, C. *Acta Chem. Scand. Ser. B* 1980, 34, 443.
- (86) Imamoto, T.; Mukaiyama, T. *Chem. Lett.* 1980, 45.
- (87) (a) Leyendecker, F.; Jesser, F.; Ruhland, B. *Tetrahedron Lett.* 1981, 22, 3601. (b) Leyendecker, F.; Jesser, F.; Laucher, D. *Tetrahedron Lett.* 1983, 24, 3513.
- (88) Corey, E. J.; Naef, R.; Hannon, F. J. *J. Am. Chem. Soc.* 1986, 108, 7114.
- (89) Tanaka, K.; Ushio, H.; Suzuki, H. *J. Chem. Soc., Chem. Commun.* 1990, 795.
- (90) Tanaka, K.; Suzuki, H. *J. Chem. Soc., Chem. Commun.* 1991, 101.
- (91) Bertz, S. H.; Dabbagh, G.; Sundararajan, G. *J. Org. Chem.* 1986, 51, 4953.
- (92) Rossiter, B. E.; Eguchi, M. Unpublished results, 1989.
- (93) Dieter, R. K.; Tokles, M. *J. Am. Chem. Soc.* 1987, 109, 2040.
- (94) Dieter, R. K.; Lagu, B.; Deo, N.; Dieter, J. W. *Tetrahedron Lett.* 1990, 31, 4105.
- (95) (a) Müller, T. Dissertation, Universität Frankfurt-am Main, 1988. (b) Quinkert, G. *Chimia* 1988, 42, 207.
- (96) Rossiter, B. E.; Eguchi, M. *Tetrahedron Lett.* 1990, 31, 965.
- (97) Rossiter, B. E.; Eguchi, M.; Hernández, A. E.; Vickers, D.; Medich, J.; Marr, J.; Heinis, D. *Tetrahedron Lett.* 1991, 32, 3973.
- (98) Rossiter, B. E.; Miao, G.; Swingle, N. M.; Eguchi, M.; Hernández, A. E.; Patterson, R. G. *Tetrahedron: Asymmetry* 1992, 3, 231.
- (99) Ahn, K.-H.; Klassen, R. B.; Lippard, S. J. *Organometallics* 1990, 9, 3178.
- (100) Bott, S. G.; Ahn, K.-H.; Lippard, S. J. *Acta Crystallogr.* 1989, C45, 1738.
- (101) Andersson, S.; Jagner, S.; Nilsson, M.; Urso, F. *J. Organomet. Chem.* 1986, 301, 257.
- (102) Gustafsson, B. *Tetrahedron* 1978, 34, 3023.
- (103) Malmberg, H.; Nilsson, M. *J. Organomet. Chem.* 1983, 243, 241.
- (104) (a) Yamamoto, K.; Iijima, M.; Ogimura, Y. *Tetrahedron Lett.* 1982, 23, 3711. (b) Yamamoto, K.; Kanoh, M.; Yamamoto, N.; Tsuji, J. *Tetrahedron Lett.* 1987, 28, 6347.
- (105) Yamamoto, K.; Iijima, M.; Ogimura, Y.; Tsuji, J. *Tetrahedron Lett.* 1984, 25, 2813.
- (106) Kretschmer, R. A. *J. Org. Chem.* 1972, 37, 2744.
- (107) (a) Langer, W.; Seebach, D. *Helv. Chim. Acta* 1979, 62, 1710. (b) Seebach, D.; Kalinowski, H.-O.; Langer, W.; Crass, G.; Wilka, E.-M. *Organic Syntheses*; Wiley: New York, 1990; Vol. VII, p 41.
- (108) (a) Leyendecker, F.; Laucher, D. *Tetrahedron Lett.* 1983, 24, 3517. (b) Leyendecker, F.; Laucher, D. *Nouv. J. Chim.* 1985, 9, 13.
- (109) van Koten, G.; Noltes, J. G. *J. Organomet. Chem.* 1979, 174, 367.
- (110) Alexakis, A.; Mutti, S.; Normant, J. F. *J. Am. Chem. Soc.* 1991, 113, 6332.
- (111) (a) Petrier, C.; Barbosa, J. C. S.; Dupuy, C.; Luche, J. L. *J. Org. Chem.* 1985, 50, 5761. (b) Barbosa, J. C. S.; Petrier, C.; Luche, J. L. *Tetrahedron Lett.* 1985, 26, 829. (c) Petrier, C.; Luche, J. L.; Dupuy, C. *Tetrahedron Lett.* 1984, 25, 3463.
- (112) Soai, K.; Yokoyama, S.; Hayasaka, T.; Ebihara, K. *J. Org. Chem.* 1988, 53, 4148.
- (113) Soai, K.; Hayasaka, T.; Ugajin, S.; Yokoyama, S. *Chem. Lett.* 1988, 1571.
- (114) Soai, K.; Hayasaka, T.; Ugajin, S. *J. Chem. Soc., Chem. Commun.* 1989, 516.
- (115) Bolm, C.; Ewald, M. *Tetrahedron Lett.* 1990, 31, 5011.
- (116) Bolm, C. *Tetrahedron: Asymmetry* 1991, 2, 701.
- (117) Soai, K.; Okudo, M.; Okamoto, M. *Tetrahedron Lett.* 1991, 32, 95.
- (118) (a) Lambert, F.; Knötter, D. M.; Janssen, M. D.; van Klaveren, M.; Boersma, J.; van Koten, G. *Tetrahedron: Asymmetry* 1991, 2, 1097. (b) van Koten, G. *J. Organomet. Chem.* 1990, 400, 283.
- (119) (a) Knötter, D. M.; Spek, A. L.; van Koten, G. *J. Chem. Soc., Chem. Commun.* 1989, 1738. (b) Knötter, D. M.; Smeets, W. J. J.; Spek, A. L.; van Koten, G. *J. Am. Chem. Soc.* 1990, 112, 5896. (c) Knötter, D. M.; van Koten, G.; van Maanen, H. L.; Grove, D. M.; Spek, A. L. *Angew. Chem., Int. Ed. Engl.* 1989, 28, 341. (d) Knötter, D. M.; van Maanen, H. L.; Grove, D. M.; Spek, A. L.; van Koten, G. *Inorg. Chem.* 1991, 30, 3309.
- (120) Isobe, M.; Kondo, S.; Nagasawa, N.; Goto, T. *Chem. Lett.* 1977, 679.
- (121) (a) Watson, R. A.; Kjonaas, R. A. *Tetrahedron Lett.* 1986, 27, 1437. (b) Kjonaas, R. A.; Hoffer, R. K. *J. Org. Chem.* 1988, 53, 4133. (c) Jansen, J. F. G. A.; Feringa, B. L. *Tetrahedron Lett.* 1988, 29, 3593.
- (122) Jansen, J. F. G. A.; Feringa, B. L. *J. Chem. Soc., Chem. Commun.* 1989, 741.
- (123) Jansen, J. F. G. A.; Feringa, B. L. *J. Org. Chem.* 1990, 55, 4168.
- (124) Tomioka, K.; Shindo, M.; Koga, K. *J. Am. Chem. Soc.* 1989, 111, 8266.